RankAlpha logo
Back to Rankings

TNON

Tenon MedicalF
Nasdaq / Health Care Equipment & Services
Last Price
$1.25-$0.08 (-6.37%)
At close · 2026-11-17
View Chart
Documents
44
Stored
Transcripts
2
Recent loaded
Latest document
2026-11-13
Related article

Document history

Transcripts and related coverage stored for TNON. Related articles may discuss other companies and are not verified issuer releases.

12 shown
Related articleQuarter not tagged2026-11-13

Tenon Medical (TNON) Q3 2026 Earnings Call Transcript

Motley Fool
Image source: The Motley Fool. Thursday, Nov. 12, 2026 - President and Chief Executive Officer - Steven Foster - Chief Financial Officer - Kevin Williamson Need a quote from a Motley Fool analyst? Email [email protected] Operator: Greetings. And welcome to the Tenon Medical third quarter 2026 financial results and Corporate Update Conference Call. As a reminder, this call is being recorded. Your hosts today are Steven Foster, President and Chief Executive Officer and Kevin Williamson, chief financial officer. Mister Foster and Mister Williamson will present results of operations for the third quarter ended 09/30/2026 and provide a corporate update. A press release detailing these results was released today and is available on the Investor Relations section of our company's website www.tenonmed.com. Before we begin the formal presentation, I would like to remind everyone that statements made on the call and webcast may include predictions, estimates and other information that might be considered forward looking. While these forward looking statements represent our current judgment of what the future holds, they are subject to risks and uncertainties that could cause actual results to differ materially. You are cautioned not to place undue reliance on these forward looking statements. Reflect our opinions only as of the date of this presentation. Please keep in mind that we are not obligating ourselves to revise or publicly release the results of any revision to these forward looking statements in light of new information or future events. For a more complete discussion of these factors and other risks, you should review our quarterly and annual reports on file with the Securities and Exchange Commission at www.sec.gov. At this time, I will turn the call over to Tenon Medical's chief executive officer, Steven Foster. Please go ahead, sir. Steven Foster: Thank you, Joe, and good afternoon, everyone. I am pleased to welcome you to today's Third Quarter 20 financial results and corporate update conference call for Tenon Medical. Third quarter revenue was 1.4 million, an increase of 22% over the third quarter of last year and 12% sequentially from the second quarter. Gross profit was $1 million, an increase of 23% over the prior year period. Gross margin was 66.3%, an improvement of 0.4% compared to the 65.9% a year ago. We delivered this growth while reducing operating…Read full document

Image source: The Motley Fool. Thursday, Nov. 12, 2026 - President and Chief Executive Officer - Steven Foster - Chief Financial Officer - Kevin Williamson Need a quote from a Motley Fool analyst? Email [email protected] Operator: Greetings. And welcome to the Tenon Medical third quarter 2026 financial results and Corporate Update Conference Call. As a reminder, this call is being recorded. Your hosts today are Steven Foster, President and Chief Executive Officer and Kevin Williamson, chief financial officer. Mister Foster and Mister Williamson will present results of operations for the third quarter ended 09/30/2026 and provide a corporate update. A press release detailing these results was released today and is available on the Investor Relations section of our company's website www.tenonmed.com. Before we begin the formal presentation, I would like to remind everyone that statements made on the call and webcast may include predictions, estimates and other information that might be considered forward looking. While these forward looking statements represent our current judgment of what the future holds, they are subject to risks and uncertainties that could cause actual results to differ materially. You are cautioned not to place undue reliance on these forward looking statements. Reflect our opinions only as of the date of this presentation. Please keep in mind that we are not obligating ourselves to revise or publicly release the results of any revision to these forward looking statements in light of new information or future events. For a more complete discussion of these factors and other risks, you should review our quarterly and annual reports on file with the Securities and Exchange Commission at www.sec.gov. At this time, I will turn the call over to Tenon Medical's chief executive officer, Steven Foster. Please go ahead, sir. Steven Foster: Thank you, Joe, and good afternoon, everyone. I am pleased to welcome you to today's Third Quarter 20 financial results and corporate update conference call for Tenon Medical. Third quarter revenue was 1.4 million, an increase of 22% over the third quarter of last year and 12% sequentially from the second quarter. Gross profit was $1 million, an increase of 23% over the prior year period. Gross margin was 66.3%, an improvement of 0.4% compared to the 65.9% a year ago. We delivered this growth while reducing operating expenses, compared to both the third quarter of 25 and the second quarter of this year. Improving our loss from operations in the period compared to both prior periods. Looking at the first 9 months as a whole, revenue was 4.1 million, an increase of 66% from the 2.5 million in the first 9 months of 25. Gross profit was 2.7 million more than double the 1.3 million in the prior year period. At a gross margin of 66.2% compared with 54.4%. Growth on the top line came from continued adoption of our Catamaran and Symmetry platforms, and completed more cases with more physician users in the quarter compared to the third quarter of 25 and Q2 of this year. Physician distributor training remains a leading indicator for us, with 36 combined training activities completed within the quarter. The improvement in gross margin was primarily driven by 2 factors: higher revenue which continues to absorb fixed costs and the benefit of lower cost of sales within our Catamaran platform. Driven by the 510 clearance we announced in early Q3 which reclassified certain instrumentation to reusable status. We believe both factors will continue to have positive impact on our gross margins as we continue to grow. Beyond the financials, a few items from the quarter are worth noting. First, on the commercial side, our investments are focused on the commercial aspect of our business. As such, we have introduced a new commercial leader to the organization. Mister Thomas Batten junior, joined Tenon as chief revenue officer effective 10/01/2026. Tom brings significant experience in building commercial teams and corporate roles, as well as an independent distributor. With particular expertise in the sacropelvic space. We plan to continue adding to our commercial organization under Tom through the hiring of direct sales representatives and onboarding of independent distributor partners as we move forward. This move also allows us to deploy other team members focus on the important product launches we are planning for through the first half of 27. On September 30, we announced a full commercial launch of our new titanium 3D printed lateral screw for the Symmetry Plus SI joint fusion system. Following a successful limited launch alpha launch, that generated approximately $1.2 million in revenue from late Q4 25 through Q3 26. The new screw is the first component of our next generation lateral SI joint fusion system our 2 platform offering continues to progress the way we had planned. With physicians evaluating Catamaran and Symmetry Plus as complementary tools offering inferior, posterior, and lateral approaches to the same anatomy. Second, as it relates to our product pipeline, we are progressing on the launches we outlined last quarter. Subsequent to quarter end on October 28, we announced the completion of the initial alpha cases of our new quick step decorticator. Which is designed to streamline SI joint decortication and simplify the Symmetry Plus surgical workflow. We are targeting full market release of quick step in the first quarter of 27. We also anticipate an early December 26 submission for a highly differentiated enhancement to the Symmetry Plus implant We believe the Symmetry Plus platform will deliver differentiated benefits in lateral and oblique procedures, with integrated decortication and grafting, combined with threaded implant technology, and anti rotation capabilities. Third, specific to intellectual property. On October 15, we announced that the US Patent and Trademark Office issued 8 new patents to the company so far in 2026, bringing our portfolio to 38 issued U. S. Patents and 9 international patents. With 31 US and foreign patent applications pending. These patents include both system and method claims covering the catamaran system, and we believe they strengthen our position as an innovator in the sacral pelvic fusion market. Fourth, as it relates to capital, we significantly strengthened our balance sheet during the quarter. We raised approximately $15.6 million in aggregate gross proceeds through a multitude of multiple transactions in the quarter. Through the prepayments made in August and September, we repaid our convertible notes in full ahead of the September 11 maturity. And regaining compliance with Nasdaq stockholder equity requirements as well as its minimum bid price requirements following our 1-for-35 split reverse split in the year. We ended the quarter with $3.8 million in cash, and cash equivalents Looking out over the balance of the year, our priorities remain consistent. Expanding physician training and adoption, across both platforms, advancing our product pipeline, and maintaining discipline on our spend. With our convertible notes that now behind us, our attention is fully on growth. We believe we have multiple ways to win in this market, and are excited about what is to come. And with that, I will turn the call over to Kevin to discuss our financials. Kevin Williamson: Thank you, Steven. I will now provide a summarized review of our financial results. A full breakdown is available in our press release that crossed the wire this afternoon. Starting with the top line, third quarter revenue was 1.4 million, up 22% from $1.2 million a year ago, and up 12% sequentially from the second quarter of this year. Revenue for the 9 months ended 09/30/2026 was 4.1 million, an increase of 66% compared to 2.5 million in the 9 months ended September 30, 2025. The increase in the quarter was driven by the continued adoption of our Catamaran and Symmetry systems. Within the quarter, we saw increased procedures, and physician users compared to both the third quarter of 25 and the second quarter of this year. We expect to continue to build on our momentum through recent and upcoming Salesforce expansion increased physician and distributor engagement, and future product launches. Gross profit was 1 million or 66.3% of revenue in the third quarter, compared to 800 thousand or 65.9% of revenue a year ago. A 23% increase in dollar terms. On a margin basis, we are up about 0.4 percentage points year over year. For the 9 months, gross profit was 2.7 million or 66.2% of revenue, compared to 1.3 million or 54.4% of revenue, a 102% increase in dollars, and roughly 11.8 percentage points of margin improvement. The increase in gross margin in the quarter and year to date periods was primarily driven by increased revenue further absorbing fixed costs within our cost of goods sold, while the third quarter also saw benefit from improved catamaran per procedure costs driven by a 510(k) clearance the company announced receiving on July 2 which reclassified certain instruments to reusable status. Moving forward, we believe our gross margin will continue to expand as revenue increases and further absorbs fixed costs. Operating expenses totaled $4 million in the third quarter, compared to $4.2 million in the third quarter of 25. For the 9 months, operating expenses totaled 12.4 million compared to $11.3 million in the prior year period. The decrease in the quarter was primarily due to lower G&A expenses primarily reflecting lower professional service fees, partially offset by higher sales and marketing expenses which were associated with increased revenue and higher R&D expenses, as we continue to work towards future product additions. Loss from operations for the third quarter improved by $300 thousand to $3.1 million from $3.4 million in the prior year period. For the 9 months, loss from operations improved by $200 thousand to $9.7 million from $9.9 million in the prior period. Net loss was $6.6 million or $5.39 per share in the third quarter compared to a net loss of $3.3 million or $14.17 per share. In the third quarter of 25. For the 9 months, net loss was $14.2 million or $22.48 per share compared to a net loss of $9.7 million or $51.72 per share in the same year ago period. As a reminder, all per share figures reflect the 1-for-35 reverse stock split we affected on August 10, 2026. The increase in net loss was primarily attributable to noncash items below the operating line. Including $3.1 million of expense related to warrants, issued as inducement consideration in connection with our September warrant inducement transaction and $700 thousand of noncash interest expense from the amortization of debt discount on our convertible notes which we repaid in full during the quarter. We ended the quarter with $8.3 million in cash and cash equivalents, compared to $3.8 million as of 12/31/2025, During the quarter, we raised approximately $15.6 million in aggregate gross proceeds and repaid in full our senior convertible notes, which had an aggregate principal amount of approximately $5.16 million ahead of their 09/11/2026 maturity date. This left us with no outstanding debt as of quarter end. Additionally, subsequent to quarter end, we increased our ATM capacity to approximately $7.1 million of availability, which we expect to support our capital needs in the future. Overall, we believe the financial and strategic actions taken during the third quarter most importantly, retiring our convertible notes and strengthening our cash position, have improved our ability to drive continued growth while sustaining a streamlined and disciplined cost base as we fund our commercial, clinical, and development priorities. I will now hand the call back to Steven for closing comments. Steven Foster: Thank you, Kevin. To conclude, Tenon is delivering top line growth with a strengthened balance sheet a disciplined cost structure that we believe will support efficiencies as we expand our offering. Our R&D investments are now converting into launches. With the full commercial launch of our 3D printed Symmetry Plus lateral screw. And quick step targeted for full market release in first quarter of 27. And additional launches that we are planning over the coming quarters. We believe our focus on commercial expansion and execution positions Tenon to build on this momentum and deliver meaningful value to patients providers, and our shareholders. I thank all of you for attending. And now I would like to hand the call back over to our operator and begin our question and answer session with covering analysts. Joe? Operator: Thank you, sir. Ladies and gentlemen, if you would like to ask a question. Please press 1 on your telephone keypad. A confirmation tone will indicate your line is in the question queue. You may press 2 if you would like to remove your question. Before pressing the star keys. 1 moment please while we poll for questions. Thank you. There are no further questions at this time. And I will turn the call back over to Steven Foster for closing remarks. Steven Foster: Thank you, Joe. I would like to thank each of you for joining our earnings conference call today. Look forward to continuing to update you on our ongoing progress and growth. If we were unable to answer any of your questions. Please reach out to our IR firm, M and Z Group, who will be more than happy to assist. Thank you Operator: Thank you. This concludes today's conference. You may disconnect your lines at this time. And we thank you for your participation. Before you buy stock in Tenon Medical, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Tenon Medical wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $338,083!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,021,163!* Now, it's worth noting Stock Advisor's total average return is 830% — a market-crushing outperformance compared to 209% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors. See the 10 stocks » *Stock Advisor returns as of November 13, 2026. This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Tenon Medical (TNON) Q3 2026 Earnings Call Transcript was originally published by The Motley Fool

Related articleQuarter not tagged2026-11-13

Tenon Medical Inc (TNON) (Q3 2026) Earnings Call Highlights: Revenue Climbs 22% as Debt Is ...

GuruFocus.com
This article first appeared on GuruFocus. - Q3 Revenue: $1.4 million, up 22% YoY and 12% sequentially. - Nine-Month Revenue: $4.1 million, up 66% from $2.5 million in the prior-year period. - Q3 Gross Profit: $1 million, up 23% YoY. - Q3 Gross Margin: 66.3%, up 0.4 percentage points from 65.9% a year ago. - Nine-Month Gross Profit: $2.7 million, up 102% from $1.3 million. - Nine-Month Gross Margin: 66.2%, up ~11.8 percentage points from 54.4%. - Q3 Operating Expenses: ~$4 million, down from $4.2 million YoY. - Nine-Month Operating Expenses: $12.4 million, up from $11.3 million. - Q3 Loss from Operations: $3.1 million, improved by $0.3 million from $3.4 million. - Nine-Month Loss from Operations: $9.7 million, improved by $0.2 million from $9.9 million. - Q3 Net Loss: $6.6 million, or $5.39 per share, vs. $3.3 million, or $14.17 per share, a year ago. - Nine-Month Net Loss: $14.2 million, or $22.48 per share, vs. $9.7 million, or $51.72 per share. - Cash and Cash Equivalents: $8.3 million at quarter end, vs. $3.8 million as of December 31, 2025. - Capital Raise: ~$15.6 million in aggregate gross proceeds during the quarter. - Debt: Repaid ~$5.16 million principal of convertible notes in full; no outstanding debt at quarter end. - ATM Capacity: Increased to ~$7.1 million of availability subsequent to quarter end. - Symmetry+ Lateral Screw: ~$1.2 million in revenue from limited alpha launch (late Q4 2025 through Q3 2026). - Training Activity: 36 combined physician/distributor training activities completed in the quarter. - Warning! GuruFocus has detected 7 Warning Signs with TNON. - Is TNON fairly valued? Test your thesis with our free DCF calculator. Release Date: November 12, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. - Third quarter revenue increased 22% year-over-year to $1.4 million and 12% sequentially, driven by continued adoption of the Catamaran and Symmetry platforms. - Gross margin improved to 66.3% in Q3 and 66.2% year-to-date, up from 65.9% and 54.4% respectively, due to higher revenue absorbing fixed costs and lower per-procedure costs from a 510 clearance. - Operating expenses decreased in Q3 compared to both the prior year and prior quarter, leading to a $0.3 million improvement in loss from operations. - The company strengthened its balance sheet by raising $15.6 million, repaying c…Read full document

This article first appeared on GuruFocus. - Q3 Revenue: $1.4 million, up 22% YoY and 12% sequentially. - Nine-Month Revenue: $4.1 million, up 66% from $2.5 million in the prior-year period. - Q3 Gross Profit: $1 million, up 23% YoY. - Q3 Gross Margin: 66.3%, up 0.4 percentage points from 65.9% a year ago. - Nine-Month Gross Profit: $2.7 million, up 102% from $1.3 million. - Nine-Month Gross Margin: 66.2%, up ~11.8 percentage points from 54.4%. - Q3 Operating Expenses: ~$4 million, down from $4.2 million YoY. - Nine-Month Operating Expenses: $12.4 million, up from $11.3 million. - Q3 Loss from Operations: $3.1 million, improved by $0.3 million from $3.4 million. - Nine-Month Loss from Operations: $9.7 million, improved by $0.2 million from $9.9 million. - Q3 Net Loss: $6.6 million, or $5.39 per share, vs. $3.3 million, or $14.17 per share, a year ago. - Nine-Month Net Loss: $14.2 million, or $22.48 per share, vs. $9.7 million, or $51.72 per share. - Cash and Cash Equivalents: $8.3 million at quarter end, vs. $3.8 million as of December 31, 2025. - Capital Raise: ~$15.6 million in aggregate gross proceeds during the quarter. - Debt: Repaid ~$5.16 million principal of convertible notes in full; no outstanding debt at quarter end. - ATM Capacity: Increased to ~$7.1 million of availability subsequent to quarter end. - Symmetry+ Lateral Screw: ~$1.2 million in revenue from limited alpha launch (late Q4 2025 through Q3 2026). - Training Activity: 36 combined physician/distributor training activities completed in the quarter. - Warning! GuruFocus has detected 7 Warning Signs with TNON. - Is TNON fairly valued? Test your thesis with our free DCF calculator. Release Date: November 12, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. - Third quarter revenue increased 22% year-over-year to $1.4 million and 12% sequentially, driven by continued adoption of the Catamaran and Symmetry platforms. - Gross margin improved to 66.3% in Q3 and 66.2% year-to-date, up from 65.9% and 54.4% respectively, due to higher revenue absorbing fixed costs and lower per-procedure costs from a 510 clearance. - Operating expenses decreased in Q3 compared to both the prior year and prior quarter, leading to a $0.3 million improvement in loss from operations. - The company strengthened its balance sheet by raising $15.6 million, repaying convertible notes in full, and ending the quarter with $8.3 million in cash and no outstanding debt. - Tenon Medical Inc (NASDAQ:TNON) expanded its intellectual property portfolio with eight new patents in 2026, bringing the total to 38 US and nine international patents, and progressed product launches including the full commercial launch of the Symmetry+ lateral screw and the upcoming QuickStep decorticator. - Net loss increased to $6.6 million in Q3 2026 from $3.3 million in Q3 2025, primarily due to non-cash expenses related to warrants and debt discount amortization. - Operating expenses for the nine months increased to $12.4 million from $11.3 million in the prior year period, driven by higher sales and marketing and R&D expenses. - Loss from operations remained significant at $3.1 million for Q3 and $9.7 million for the nine months, indicating ongoing profitability challenges. - The company relies on future product launches, such as QuickStep targeted for Q1 2027, which may face delays or not achieve expected market acceptance. - Despite revenue growth, the company continues to incur net losses and may require additional capital, as evidenced by the increased ATM capacity to $7.1 million. Q: What drove Tenon Medical's third-quarter revenue growth, and how did margins trend? A: CEO Steven Foster reported Q3 2026 revenue of $1.4 million, up 22% year over year and 12% sequentially, driven by continued adoption of the Catamaran and Symmetry platforms and more cases with more physician users. Gross profit was $1 million (66.3% margin), up 23% in dollars and 0.4 points in margin versus 65.9% a year ago. For the first nine months, revenue was $4.1 million, up 66% from $2.5 million, with gross margin of 66.2% versus 54.4%. Q: What factors are expected to support further gross margin expansion? A: CFO Kevin Williamson said margin gains came from higher revenue absorbing fixed costs, plus lower Catamaran per-procedure costs after a July 2, 2026 510 clearance reclassified certain instruments as reusable. He expects gross margin to continue expanding as revenue grows and further absorbs fixed costs. Q: How did operating expenses and the operating loss trend in the quarter? A: Williamson said Q3 operating expenses totaled $4 million, down from $4.2 million a year ago, mainly on lower G&A and professional fees, partly offset by higher sales and marketing and R&D. Loss from operations improved to $3.1 million from $3.4 million. For the nine months, opex was $12.4 million versus $11.3 million, while the operating loss improved to $9.7 million from $9.9 million. Q: Why did net loss widen despite improved operating results? A: Williamson attributed the Q3 net loss of $6.6 million ($5.39 per share) versus $3.3 million ($14.17 per share) a year ago to non-cash items below the operating line: $3.1 million of warrant inducement expense from the September transaction and $0.7 million of non-cash interest from convertible note discount amortization. Per-share figures reflect the 1-for-35 reverse split effective August 10, 2026. Q: What is the status of Tenon's balance sheet and capital position? A: The company raised about $15.6 million in gross proceeds during the quarter and repaid its senior convertible notes (roughly $5.16 million principal) in full ahead of the September 11, 2026 maturity, leaving no outstanding debt. It ended the quarter with $8.3 million in cash versus $3.8 million at December 31, 2025, and later expanded ATM capacity to about $7.1 million. Foster noted the company regained Nasdaq compliance on stockholder equity and minimum bid price. Q: What is the commercial strategy behind the new Chief Revenue Officer hire? A: Foster said Thomas Batten Jr. joined as Chief Revenue Officer effective October 1, 2026, bringing experience building commercial teams and expertise in the sacral pelvic space as an independent distributor. Tenon plans to add direct sales reps and independent distributor partners under him, while redeploying other team members to focus on product launches planned through the first half of 2027. Q: What is the launch status of the Symmetry+ 3D-printed lateral screw? A: Foster said Tenon announced full commercial launch of the titanium 3D-printed lateral screw on September 30, 2026, following a limited alpha launch that generated approximately $1.2 million in revenue from late Q4 2025 through Q3 2026. It is the first component of the next-generation lateral SI joint fusion system, with physicians evaluating Catamaran and Symmetry+ as complementary posterior/inferior and lateral approaches. Q: What is the timeline for the QuickStep decorticator and the Symmetry+ implant enhancement? A: Foster said initial alpha cases of the QuickStep decorticator, designed to streamline SI joint decortication and simplify the Symmetry+ workflow, were completed and announced October 28, 2026, with full market release targeted for Q1 2027. Tenon also anticipates an early December 2026 submission for a differentiated Symmetry+ implant enhancement featuring integrated decortication and grafting, threaded implant technology, and anti-rotation capabilities. Q: How is Tenon's intellectual property portfolio developing? A: Foster said the USPTO issued eight new patents to Tenon in 2026 as of the October 15 announcement, bringing the portfolio to 38 issued US patents and nine international patents, with 31 US and foreign applications pending. The patents include system and method claims covering the Catamaran system, which the company believes strengthens its position as an innovator in the sacral pelvic fusion market. Q: What are management's priorities for the remainder of 2026? A: Foster said priorities remain consistent: expanding physician training and adoption across both platforms (36 combined training activities in Q3), advancing the product pipeline, and maintaining spending discipline. With convertible notes retired, he said attention is fully on growth, and management believes the company has multiple ways to win in the market. Q: Did analysts ask any questions during the Q&A session? A: No. The operator opened the line for questions and stated there were none at that time, after which Foster delivered closing remarks, thanking participants and directing any unanswered questions to the company's IR firm, MZ Group. For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Related articleQuarter not tagged2026-11-12

Tenon(R) Medical Reports Third Quarter 2026 Financial Results

ACCESS Newswire
~ Third Quarter 2026 Revenue of $1.4 Million, a 22% Increase Compared to Prior Year ~ ~ Third Quarter Gross Profit of $1.0 Million, a 23% Increase Compared to Prior Year; Gross Margin of 66.3% ~ ~ Raised Approximately $15.6 Million in Gross Proceeds, Repaid Convertible Notes in Full and Ended the Quarter with $8.3 Million in Cash and Cash Equivalents ~ ~ Commenced Full Commercial Launch of 3D-Printed Lateral Screw for the SImmetry®+ SI Joint Fusion System ~ ~ Added Eight New U.S. Patents in 2026, Bringing Portfolio to 38 Issued U.S. Patents ~ LOS GATOS, CA / ACCESS Newswire / November 12, 2026 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon Medical" or the "Company"), a company redefining care for patients with sacro-pelvic disorders, today reported financial results for the third quarter ended September 30, 2026. Financial Results and Business Updates - Third Quarter 2026 Results: - Third quarter revenue of $1.4 million, an increase of 22% compared to $1.2 million in the third quarter of 2025. - Third quarter gross profit of $1.0 million, an increase of 23% compared to $0.8 million in the third quarter of 2025. - Gross margin of 66.3%, a 0.4 percentage point increase from 65.9% in the third quarter of 2025. - Cash and cash equivalents of $8.3 million as of September 30, 2026, compared to $3.8 million as of December 31, 2025. - Operating loss of $3.1 million in the third quarter, an improvement of $0.3 million compared to $3.4 million in the third quarter of 2025. - Net loss of $6.6 million, or $5.39 per share, in the third quarter of 2026, compared to a net loss of $3.3 million, or $14.17 per share, in the third quarter of 2025. - Commercially launched the 3D-printed lateral screw for the SImmetry®+ SI Joint Fusion System, the first component of a next-generation lateral system, following an alpha launch that generated approximately $1.2 million in revenue from late in the fourth quarter of 2025 through the third quarter of 2026. - Raised approximately $15.6 million in aggregate gross proceeds and regained compliance with Nasdaq's minimum stockholders' equity requirement. The Company also regained compliance with Nasdaq's minimum bid price requirement following its 1-for-35 reverse stock split, effective August 10, 2026. - Repaid in full approximately $5.12 million of remaining principal balance of senior convertible notes ahead of their September 11, 2026…Read full document

~ Third Quarter 2026 Revenue of $1.4 Million, a 22% Increase Compared to Prior Year ~ ~ Third Quarter Gross Profit of $1.0 Million, a 23% Increase Compared to Prior Year; Gross Margin of 66.3% ~ ~ Raised Approximately $15.6 Million in Gross Proceeds, Repaid Convertible Notes in Full and Ended the Quarter with $8.3 Million in Cash and Cash Equivalents ~ ~ Commenced Full Commercial Launch of 3D-Printed Lateral Screw for the SImmetry®+ SI Joint Fusion System ~ ~ Added Eight New U.S. Patents in 2026, Bringing Portfolio to 38 Issued U.S. Patents ~ LOS GATOS, CA / ACCESS Newswire / November 12, 2026 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon Medical" or the "Company"), a company redefining care for patients with sacro-pelvic disorders, today reported financial results for the third quarter ended September 30, 2026. Financial Results and Business Updates - Third Quarter 2026 Results: - Third quarter revenue of $1.4 million, an increase of 22% compared to $1.2 million in the third quarter of 2025. - Third quarter gross profit of $1.0 million, an increase of 23% compared to $0.8 million in the third quarter of 2025. - Gross margin of 66.3%, a 0.4 percentage point increase from 65.9% in the third quarter of 2025. - Cash and cash equivalents of $8.3 million as of September 30, 2026, compared to $3.8 million as of December 31, 2025. - Operating loss of $3.1 million in the third quarter, an improvement of $0.3 million compared to $3.4 million in the third quarter of 2025. - Net loss of $6.6 million, or $5.39 per share, in the third quarter of 2026, compared to a net loss of $3.3 million, or $14.17 per share, in the third quarter of 2025. - Commercially launched the 3D-printed lateral screw for the SImmetry®+ SI Joint Fusion System, the first component of a next-generation lateral system, following an alpha launch that generated approximately $1.2 million in revenue from late in the fourth quarter of 2025 through the third quarter of 2026. - Raised approximately $15.6 million in aggregate gross proceeds and regained compliance with Nasdaq's minimum stockholders' equity requirement. The Company also regained compliance with Nasdaq's minimum bid price requirement following its 1-for-35 reverse stock split, effective August 10, 2026. - Repaid in full approximately $5.12 million of remaining principal balance of senior convertible notes ahead of their September 11, 2026 maturity. Subsequent Updates - The Company hired Thomas Batton Jr. as Chief Revenue Officer, effective October 1, 2026, to lead the commercial organization. Mr. Batton has over 15 years of medical device sales and commercial leadership experience across spine, neuromodulation and pain management, including extensive experience within SI joint fixation. The Company plans to continue to add to its commercial organization through hiring direct sales representatives and onboarding distributor partners. - On October 15, 2026, the Company announced that the U.S. Patent and Trademark Office had issued eight new patents to the Company so far in 2026, bringing its portfolio to 38 issued U.S. patents and nine international patents, with 31 U.S. and foreign patent applications pending. The patents include both system and method claims covering the Catamaran® SI Joint Fusion System and are expected to strengthen the Company's intellectual property position in the sacro-pelvic fusion market. - On October 28, 2026, the Company announced the completion of the initial alpha cases of its new Quickstep™ Decorticator for the next-generation SImmetry®+ SI Joint Fusion System. Quickstep is designed to streamline joint decortication and simplify the SImmetry+ surgical workflow, and the Company is targeting full market release in the first quarter of 2027. "Third quarter revenue of $1.4 million grew 22% compared to the prior year and 12% sequentially from the second quarter, and we delivered that growth while reducing operating expenses compared to both the third quarter of 2025 and the second quarter of this year," said Steven M. Foster, President and CEO of Tenon Medical, Inc. "Just as importantly, we significantly strengthened our balance sheet during the quarter. We raised approximately $15.6 million in aggregate gross proceeds, repaid our convertible notes in full, regained compliance with Nasdaq's stockholders' equity and minimum bid price requirements, and ended the quarter with $8.3 million in cash." "With our convertible notes now behind us, our attention is fully on growth. The full commercial launch of our 3D-printed SImmetry®+ lateral screw, the first component of our next-generation lateral system, and the completion of initial alpha cases with our Quickstep™ Decorticator, which we are targeting for full market release in the first quarter of 2027, expand the tools we can offer our physician partners. Our eight new U.S. patents this year further strengthen the protection around our Catamaran® platform. For the balance of 2026, our priorities remain consistent: expanding physician training and adoption across both platforms, advancing our product pipeline, and maintaining discipline on spend." Third Quarter 2026 Financial Results Revenue was $1.4 million in the third quarter of 2026, an increase of 22% compared to $1.2 million in the same period of 2025. Revenue for the nine months ended September 30, 2026 was $4.1 million, an increase of 66% compared to $2.5 million in the nine months ended September 30, 2025. The increase in revenue for the three months ended September 30, 2026 as compared to 2025 was primarily due to an increase in the number of surgical procedures, including continued adoption of the SImmetry®+ System. Gross profit was $1.0 million, or 66.3% of revenue, in the third quarter of 2026, compared to $0.8 million, or 65.9% of revenue, in the third quarter of 2025. For the nine months ended September 30, 2026, gross profit was $2.7 million, or 66.2% of revenue, compared to $1.3 million, or 54.4% of revenue, for the nine months ended September 30, 2025. The 0.4 percentage point gross margin increase in the three months ended September 30, 2026 was primarily driven by increased revenue, further absorbing fixed costs within costs of goods sold, as well as improved Catamaran® per-procedure costs, driven by the 510(k) clearance the Company announced receiving on July 2, 2026, which reclassifies certain instruments to reusable status. Operating expenses totaled $4.0 million in the third quarter of 2026, compared to $4.2 million in the third quarter of 2025. For the nine months ended September 30, 2026, operating expenses totaled $12.4 million, compared to $11.3 million in the prior year period. The decrease in the three months ended September 30, 2026 was primarily due to lower general and administrative expenses, primarily reflecting lower professional service fees, partially offset by higher sales and marketing expenses associated with higher revenue and higher research and development expenses as the Company continues to work towards future product additions. Net loss was $6.6 million, or $5.39 per share, in the third quarter of 2026, compared to a net loss of $3.3 million, or $14.17 per share, in the third quarter of 2025. For the nine months ended September 30, 2026, net loss was $14.2 million, or $22.48 per share, compared to a net loss of $9.7 million, or $51.72 per share, in the same year ago period. The increase in net loss in the third quarter of 2026 was primarily attributable to non-cash items below the operating line, including $3.1 million of expense related to warrants issued as inducement consideration and $0.7 million of non-cash interest expense from the amortization of debt discount on the Company's convertible notes, which were repaid in full during the quarter. Loss from operations improved to $3.1 million from $3.4 million in the prior year period. As of September 30, 2026, cash and cash equivalents totaled $8.3 million, compared to $3.8 million at December 31, 2025. During the third quarter of 2026, the Company raised approximately $10.1 million in aggregate gross proceeds through a $4.2 million public offering completed on July 1, 2026, a $3.0 million private placement closed on August 31, 2026, and a warrant inducement transaction in September 2026 for gross proceeds of approximately $2.9 million. The Company also received approximately $2.8 million in gross proceeds from the sale of common stock under its at-the-market offering program and approximately $2.7 million from the exercise of warrants during the quarter, bringing total gross proceeds for the third quarter to approximately $15.6 million. Through prepayments made in August and September 2026, the Company repaid in full its senior convertible notes, which had an aggregate principal amount of approximately $5.16 million, ahead of their September 11, 2026 maturity date, as announced on September 9, 2026. The Company had no outstanding debt as of quarter-end, positioning it to continue executing on its strategic initiatives, including the continued development and launch of the acquired SiVantage assets and expanding the commercial team. Third Quarter 2026 Earnings Conference Call Management will host a conference call at 4:30 p.m. ET (1:30 p.m. PT) today, November 12, 2026, to discuss Tenon's third quarter 2026 financial results, provide a corporate update, and conclude with Q&A with the Company's covering analysts. To participate, please use the following information: Date: | Thursday, November 12, 2026 Time: | 4:30 p.m. Eastern time Dial-in: | 1-877-407-0792 International Dial-in: | 1-201-689-8263 Webcast: | TNON Conference Call Please dial in at least 10 minutes before the start of the call to ensure timely participation. An audio playback of the call will be available through November 26, 2026, on Tenon's Investor Relations website at http://ir.tenonmed.com/ or via telephone replay by dialing 1-844-512-2921 (USA) or 1-412-317-6671 (International). The access code will be 13763354. About Tenon Medical, Inc. Tenon Medical, Inc. is a medical device company dedicated to transforming care for patients with certain sacro-pelvic disorders. Tenon was incorporated in the State of Delaware in 2012 and currently offers two systems to treat a diseased sacroiliac joint (the "SI Joint"). The Company has developed The Catamaran® SI Joint Fusion System ("The Catamaran System") that offers a novel, less invasive approach to the SI Joint using a single, robust titanium implant. In August 2025, the Company acquired substantially all the assets of SiVantage, Inc. and SIMPL Medical, LLC, including the SImmetry+® SI Joint Fusion System, which treats disorders of the SI Joint through a minimally invasive lateral access solution that incorporates well-established orthopedic fusion principles. Since the national launch of The Catamaran System in October 2022, Tenon has been focused on three commercial opportunities: 1) primary SI Joint procedures, 2) revision procedures of failed SI Joint implants and 3) SI-Joint fusion adjunct to a spine fusion construct. For more information, please visit www.tenonmed.com. Information on the Company's website does not constitute a part of and is not incorporated by reference into this press release. The Tenon Medical logo shown above, and Catamaran®, PiSIF®, CAT PiSIF®, ETAD®, Posterior Inferior Sacroiliac Fusion®, CAT SIJ Fusion System®, Catamaran SIJ Fusion System®, Catamaran Inferior Posterior Fusion System®, Catamaran Transfixation Fusion System®, Catamaran Transfixation Fusion Device® and SImmetry® are registered trademarks of Tenon Medical, Inc. MAINSAILTM, SImmetry+ and QuickstepTM are also trademarks of Tenon Medical, Inc. Safe Harbor This press release contains "forward-looking statements," which are statements related to events, results, activities or developments that Tenon expects, believes or anticipates will or may occur in the future. Forward-looking statements often contain words such as "intends," "estimates," "anticipates," "hopes," "projects," "plans," "expects," "seek," "believes," "see," "should," "will," "would," "target," and similar expressions and the negative versions thereof. These forward-looking statements include, but are not limited to, statements regarding the Company's commercial and product development plans, including the anticipated full market release of the Quickstep™ Decorticator, the expansion of its commercial organization, its intellectual property position and its strategic priorities. Such statements are based on Tenon's experience and perception of current conditions, trends, expected future developments and other factors it believes are appropriate under the circumstances, and speak only as of the date made. Forward-looking statements are inherently uncertain and actual results may differ materially from assumptions, estimates or expectations reflected or contained in the forward-looking statements as a result of various factors, including the Company's need to raise additional capital and the substantial doubt about its ability to continue as a going concern. For details on the uncertainties that may cause Tenon's actual results to be materially different than those expressed in any forward-looking statements, please review Tenon's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as updated from time to time in our Quarterly Reports on Form 10-Q and in our other public filings on file with the SEC at www.sec.gov, particularly the information contained in the section entitled "Risk Factors." We undertake no obligation to publicly update or revise any forward-looking statements to reflect new information or future events or otherwise unless required by law. IR Contact: Shannon Devine 203-741-8811 MZ North America [email protected] Tenon Medical, Inc. Condensed Balance Sheets (Unaudited) (In thousands, except share data) | | September 30, | | | December 31, | | | 2026 | | | 2025 | ASSETS | | | | | | Current assets: | | | | | | Cash and cash equivalents | | $ | 8,271 | | | $ | 3,756 | Accounts receivable, net | | | 1,701 | | | | 1,698 | Inventory | | | 882 | | | | 1,054 | Prepaid expenses and other current assets | | | 367 | | | | 260 | Total current assets | | | 11,221 | | | | 6,768 | Property and equipment, net | | | 717 | | | | 918 | Deposits | | | 51 | | | | 51 | Operating lease right-of-use asset | | | 1,362 | | | | 131 | Intangible assets, net | | | 441 | | | | 485 | Goodwill | | | 2,407 | | | | 2,407 | TOTAL ASSETS | | $ | 16,199 | | | $ | 10,760 | | | | | | | | | LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: | | | | | | | | Accounts payable | | $ | 657 | | | $ | 845 | Accrued expenses | | | 2,151 | | | | 1,637 | Current portion of accrued commissions | | | 780 | | | | 590 | Current portion of operating lease liability | | | 222 | | | | 141 | Current portion of contingent consideration | | | 23 | | | | - | Total current liabilities | | | 3,833 | | | | 3,213 | Accrued commissions, net of current portion | | | 1,086 | | | | 1,514 | Operating lease liability, net of current portion | | | 1,071 | | | | - | Contingent consideration, net of current portion | | | 991 | | | | 993 | Total liabilities | | | 6,981 | | | | 5,720 | Stockholders' equity: | | | | | | | | Series A convertible preferred stock, $0.001 par value; 4,500,000 shares authorized at September 30, 2026 and December 31, 2025; 204,159 shares issued and outstanding at September 30, 2026 and December 31, 2025 | | | 2,622 | | | | 2,622 | Series B convertible preferred stock, $0.001 par value; 491,222 shares authorized at September 30, 2026 and December 31, 2025; 86,454 shares issued and outstanding at September 30, 2026 and December 31, 2025 | | | 452 | | | | 452 | Common stock, $0.001 par value; 130,000,000 shares authorized at September 30, 2026 and December 31, 2025; 2,682,721 and 310,036 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively | | | 3 | | | | - | Additional paid-in capital | | | 101,608 | | | | 83,268 | Accumulated deficit | | | (95,467 | ) | | | (81,302 | ) Total stockholders' equity | | | 9,218 | | | | 5,040 | TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | | $ | 16,199 | | | $ | 10,760 | Tenon Medical, Inc. Condensed Statements of Operations and Comprehensive Loss (Unaudited) (In thousands, except per share data) | | Three Months Ended September 30, | | | Nine Months Ended September 30, | | | 2026 | | | 2025 | | | 2026 | | | 2025 | Revenue | | $ | 1,432 | | | $ | 1,173 | | | $ | 4,090 | | | $ | 2,463 | Cost of sales | | | 482 | | | | 400 | | | | 1,381 | | | | 1,122 | Gross Profit | | | 950 | | | | 773 | | | | 2,709 | | | | 1,341 | | | | | | | | | | | | | | | | | Operating Expenses | | | | | | | | | | | | | | | | Research and development | | | 804 | | | | 428 | | | | 2,234 | | | | 1,622 | Sales and marketing | | | 1,714 | | | | 1,538 | | | | 5,441 | | | | 4,304 | General and administrative | | | 1,517 | | | | 2,199 | | | | 4,753 | | | | 5,341 | Total Operating Expenses | | | 4,035 | | | | 4,165 | | | | 12,428 | | | | 11,267 | | | | | | | | | | | | | | | | | Loss from Operations | | | (3,085 | ) | | | (3,392 | ) | | | (9,719 | ) | | | (9,926 | ) | | | | | | | | | | | | | | | | Other Income (Expense) | | | | | | | | | | | | | | | | Gain on investments | | | 43 | | | | 53 | | | | 92 | | | | 202 | Interest expense | | | (719 | ) | | | - | | | | (1,747 | ) | | | - | Other income (expense), net | | | (2,878 | ) | | | - | | | | (2,791 | ) | | | - | Total Other (Expense) Income, net | | | (3,554 | ) | | | 53 | | | | (4,446 | ) | | | 202 | Net Loss and Comprehensive Loss | | $ | (6,639 | ) | | $ | (3,339 | ) | | $ | (14,165 | ) | | $ | (9,724 | ) Net Loss Per Share of Common Stock | | | | | | | | | | | | | | | | Basic and diluted | | $ | (5.39 | ) | | $ | (14.17 | ) | | $ | (22.48 | ) | | $ | (51.72 | ) | | | | | | | | | | | | | | | | Weighted-Average Shares of Common Stock Outstanding | | | | | | | | | | | | | | | | Basic and diluted | | | 1,231 | | | | 236 | | | | 630 | | | | 188 | SOURCE: Tenon Medical View the original press release on ACCESS Newswire

TranscriptFY2026 Q32026-11-12

FY2026 Q3 earnings call transcript

Earnings source - 18 paragraphs
Operator

Greetings, and welcome to the Tenon Medical Third Quarter 2026 Financial Results and Corporate Update Conference Call. As a reminder, this call is being recorded. Your hosts today are Steve Foster, President and Chief Executive Officer, and Kevin Williamson, Chief Financial Officer. Mr. Foster and Mr. Williamson will present results of operations for the third quarter ended September 30, 2026, and provide a corporate update. A press release detailing these results was released today and is available on the investor relations section of our company's website, www.tenonmed.com. Before we begin the formal presentation, I would like to remind everyone that statements made on the call and webcast may include predictions, estimates, and other information that might be considered forward-looking. While these forward-looking statements represent our current judgment of what the future holds, they are subject to risks and uncertainties that could cause actual results to differ materially.

Operator

You are cautioned not to place undue reliance on these forward-looking statements, which reflect our opinions only as of the date of this presentation. Please keep in mind that we are not obligating ourselves to revise or publicly release the results of any revision to these forward-looking statements in light of new information or future events. For a more complete discussion of these factors and other risks, you should review our quarterly and annual reports on file with the Securities and Exchange Commission at www.sec.gov. At this time, I'll turn the call over to Tenon Medical's Chief Executive Officer, Steve Foster. Please go ahead, sir.

Steve Foster

Thank you, Joe, and good afternoon, everyone. I'm pleased to welcome you to today's third quarter 2026 financial results and corporate update conference call for Tenon Medical. Third quarter revenue was $1.4 million, an increase of 22% over the third quarter of last year, and 12% sequentially from the second quarter. Gross profit was $1 million, an increase of 23% over the prior year period. Gross margin was 66.3%, an improvement of 0.4 percentage points compared to the 65.9% a year ago. We delivered this growth while reducing operating expenses compared to both the third quarter of 2025 and the second quarter of this year, improving our loss from operations in the period compared to both prior periods. Looking at the first nine months as a whole, revenue was $4.1 million, an increase of 66% from the $2.5 million in the first nine months of 2025.

Steve Foster

Gross profit was $2.7 million, more than double the $1.3 million in the prior year period, at a gross margin of 66.2% compared with 54.4%. Growth on the top line came from continued adoption of our Catamaran and SImmetry platforms. We completed more cases with more physician users in the quarter compared to the third quarter of 2025 and Q2 of this year. Physician and distributor training remains a leading indicator for us, with 36 combined training activities completed within the quarter. The improvement in gross margin was primarily driven by two factors: higher revenue, which continues to absorb fixed costs, and the benefit of lower cost of sales within our Catamaran platform, driven by the 510(k) clearance we announced in early Q3, which reclassified certain instrumentation to reusable status. We believe both factors will continue to have positive impact on our gross margins as we continue to grow.

Steve Foster

Beyond the financials, a few items from the quarter are worth noting. First, on the commercial side, our investments are focused on the commercial aspect of our business. As such, we have introduced a new commercial leader to the organization. Mr. Thomas Batton Jr. joined Tenon as Chief Revenue Officer effective October 1, 2026. Tom brings significant experience in building commercial teams and corporate roles, as well as an independent distributor, with particular expertise in the sacro-pelvic space. We plan to continue adding to our commercial organization under Tom through the hiring of direct sales representatives and onboarding of independent distributor partners as we move forward. This move also allows us to deploy other team members to focus on the important product launches we are planning for through the first half of 2027.

Steve Foster

On September 30, we announced a full commercial launch of our new titanium 3D-printed lateral screw for the SImmetry+ SI joint fusion system, following a successful limited launch, alpha launch, that generated approximately $1.2 million in revenue from late Q4 2025 through Q3 2026. The new screw is the first component of our next-generation lateral SI joint fusion system. Our two-platform offering continues to progress the way we had planned, with physicians evaluating Catamaran and SImmetry+ as complementary tools, offering inferior-posterior and lateral approaches to the same anatomy. Second, as it relates to our product pipeline, we are progressing on the launches we outlined last quarter. Subsequent quarter end on October 28, we announced the completion of the initial alpha cases of our new Quickstep Decorticator, which is designed to streamline SI joint decortication and simplify the SImmetry+ surgical workflow.

Steve Foster

We are targeting full market release of Quickstep in the first quarter of 2027. We also anticipate an early December 2026 submission for a highly differentiated enhancement to the SImmetry+ implant. We believe the SImmetry+ platform will deliver differentiated benefits in lateral and oblique procedures with integrated decortication and grafting, combined with threaded implant technology and anti-rotation capabilities. Third, specific to intellectual property, on October 15, we announced that the U.S. Patent and Trademark Office issued eight new patents to the company so far in 2026, bringing our portfolio to 38 issued U.S. patents and nine international patents, with 31 U.S. and foreign patent applications pending. These patents include both system and method claims covering the Catamaran System, and we believe they strengthen our position as an innovator in the sacro-pelvic fusion market. Fourth, as it relates to capital, we significantly strengthened our balance sheet during the quarter.

Steve Foster

We raised approximately $15.6 million in aggregate gross proceeds through multiple transactions in the quarter. Through the prepayments made in August and September, we repaid our convertible notes in full ahead of the September 11 maturity and regained compliance with Nasdaq stockholder equity requirements, as well as its minimum bid price requirements following our 1-for-35 reverse split in the year. We ended the quarter with $8.3 million in cash and cash equivalents. Looking out over the balance of the year, our priorities remain consistent: expanding physician training and adoption across both platforms, advancing our product pipeline, and maintaining discipline on our spend. With our convertible notes now behind us, our attention is fully on growth. We believe we have multiple ways to win in this market and are excited about what is to come. With that, I will turn the call over to Kevin to discuss our financials.

Kevin Williamson

Thank you, Steve. I will now provide a summarized review of our financial results. A full breakdown is available in our press release that crossed the wire this afternoon. Starting with the top line, third quarter revenue was $1.4 million, up 22% from $1.2 million a year ago, and up 12% sequentially from the second quarter of this year. Revenue for the nine months ended September 30, 2026, was $4.1 million, an increase of 66% compared to $2.5 million in the nine months ended September 30, 2025. The increase in the quarter was driven by the continued adoption of our Catamaran and SImmetry systems. Within the quarter, we saw increased procedures and physician users compared to both the third quarter of 2025 and the second quarter of this year.

Kevin Williamson

We expect to continue to build on our momentum through recent and upcoming sales force expansion, increased physician and distributor engagement, and future product launches. Gross profit was $1 million, or 66.3% of revenue in the third quarter, compared to $0.8 million, or 65.9% of revenue a year ago, a 23% increase in dollar terms. On a margin basis, we were up about 0.4 percentage points year-over-year. For the nine months, gross profit was $2.7 million, or 66.2% of revenue, compared to $1.3 million, or 54.4% of revenue, a 102% increase in dollars and roughly 11.8 percentage points of margin improvement.

Kevin Williamson

The increase in gross margin in the quarter and year-to-date periods was primarily driven by increased revenue, further absorbing fixed costs within our cost of goods sold, while the third quarter also saw benefit from improved Catamaran per-procedure costs, driven by a 510(k) clearance the company announced receiving on July 2nd, which reclasses certain instruments to reusable status. Moving forward, we believe our gross margin will continue to expand as revenue increases and further absorbs fixed costs. Operating expenses totaled $4 million in the third quarter, compared to $4.2 million in the third quarter of 2025. For the nine months, operating expenses totaled $12.4 million, compared to $11.3 million in the prior year period.

Kevin Williamson

The decrease in the quarter was primarily due to lower G&A expenses, primarily reflecting lower professional service fees, partially offset by higher sales and marketing expenses, which were associated with increased revenue, and higher R&D expenses as we continue to work towards future product additions. Loss from operations for the third quarter improved by $0.3 million to $3.1 million from $3.4 million in the prior year period. For the nine months, loss from operations improved by $0.2 million to $9.7 million from $9.9 million in the prior period. Net loss was $6.6 million, or $5.39 per share in the third quarter, compared to a net loss of $3.3 million, or $14.17 per share in the third quarter of 2025.

Kevin Williamson

For the nine months, net loss was $14.2 million, or $22.48 per share, compared to a net loss of $9.7 million, or $51.72 per share in the same year-ago period. As a reminder, all per-share figures reflect the 1-for-35 reverse stock split we affected on August 10, 2026. The increase in net loss was primarily attributable to non-cash items below the operating line, including $3.1 million of expense related to warrants issued as inducement consideration in connection with our September warrant inducement transaction. And $0.7 million of non-cash interest expense from the amortization of debt discount on our convertible notes, which we repaid in full during the quarter. We ended the quarter with $8.3 million in cash and cash equivalents, compared to $3.8 million as of December 31, 2025.

Kevin Williamson

During the quarter, we raised approximately $15.6 million in aggregate gross proceeds and repaid in full our senior convertible notes, which had an aggregate principal amount of approximately $5.16 million ahead of their September 11, 2026 maturity date. This left us with no outstanding debt as of quarter end. Additionally, subsequent to quarter end, we increased our ATM capacity to approximately $7.1 million of availability, which we expect to support our capital needs in the future. Overall, we believe the financial and strategic actions taken during the third quarter, most importantly retiring our convertible notes and strengthening our cash position, have improved our ability to drive continued growth while sustaining a streamlined and disciplined cost base as we fund our commercial, clinical, and development priorities. I'll now hand the call back to Steve for closing comments.

Steve Foster

Thank you, Kevin. To conclude, Tenon is delivering top-line growth with a strengthened balance sheet and a disciplined cost structure that we believe will support efficiencies as we expand our offering. Our R&D investments are now converting into launches, with the full commercial launch of our 3D-printed SImmetry+ lateral screw and Quickstep targeted for full market release in the first quarter of 2027, and additional launches that we are planning over the coming quarters. We believe our focus on commercial expansion and execution positions Tenon to build on this momentum and deliver meaningful value to patients, providers, and our shareholders. I thank all of you for attending, and now I'd like to hand the call back over to our Operator to begin our question-and-answer session with covering analysts. Joe?

Operator

Thank you, sir. Ladies and gentlemen, if you would like to ask a question, please press star one on your telephone keypad, and a confirmation tone will indicate your line is in the question queue. You may press star two if you would like to remove your question from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star keys. One moment, please, while we poll for questions. Thank you. There are no further questions at this time, and I'll turn the call back over to Steve Foster for closing remarks.

Steve Foster

Very good. Thank you, Joe. I would like to thank each of you for joining our earnings conference call today and look forward to continuing to update you on our ongoing progress and growth. If we were unable to answer any of your questions, please reach out to our IR firm, MZ Group. We will be more than happy to assist. Thank you.

Operator

Thank you. This concludes today's conference. You may disconnect your lines at this time, and we thank you for your participation.

Related articleQuarter not tagged2026-11-11

Earnings To Watch: Tenon Medical Inc (TNON) Q3 2026 -- GF Value Sees 252% Upside

GuruFocus.com

This article first appeared on GuruFocus. Tenon Medical Inc (NASDAQ:TNON) is set to release its Q3 2026 earnings on Nov 12, 2026. The consensus estimate for Q3 2026 revenue is 1.55 million, and the earnings are expected to come in at -5.26 per share. The full year 2026's revenue is expected to be $6.02 million and the earnings are expected to be $-23.75 per share. More detailed estimate data can be found on the Forecast page - Warning! GuruFocus has detected 7 Warning Signs with TNON. - Is TNON fairly valued? Test your thesis with our free DCF calculator. Over the past 90 days, revenue estimates for Tenon Medical Inc (NASDAQ:TNON) have declined from $6.59 million to $6.02 million for the full year 2026 and from $9.71 million to $8.87 million for 2027. Meanwhile, earnings estimates have increased from $-29.58 per share to $-23.75 per share for the full year 2026 and from $-21.18 per share to $-12.02 per share for 2027. In the previous quarter of 2026-06-30, Tenon Medical Inc's (NASDAQ:TNON) actual revenue was $1.28 million, which missed analysts' revenue expectations of $1.54 million by -16.95%. Tenon Medical Inc's (NASDAQ:TNON) actual earnings were $-12.35 per share, which missed analysts' earnings expectations of $-8.4 per share by -47.02%. After releasing the results, Tenon Medical Inc (NASDAQ:TNON) was down by -13.42% in one day. in one day. Based on the one-year price targets offered by 2 analysts, the average target price for Tenon Medical Inc (NASDAQ:TNON) is $10.5 with a high estimate of $11 and a low estimate of $10. The average target implies an upside of 503.45% from the current price of $1.74. Based on GuruFocus estimates, the estimated GF Value for Tenon Medical Inc (NASDAQ:TNON) in one year is $6.13, suggesting an upside of 252.3% from the current price of $1.74. Based on the consensus recommendation from 2 brokerage firms, Tenon Medical Inc's (NASDAQ:TNON) average brokerage recommendation is currently 2.0, indicating a "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.

Related articleQuarter not tagged2026-10-29

Tenon Medical, Inc. Sets Date for Third Quarter 2026 Earnings

ACCESS Newswire
LOS GATOS, CA / ACCESS Newswire / October 29, 2026 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company redefining care for patients with sacro-pelvic disorders, today announced plans to release financial results for the third quarter ended September 30, 2026 after market close on Thursday, November 12, 2026. The Company will also hold a conference call on the same day at 4:30 p.m. Eastern Time to discuss its financial results in further detail. The call will conclude with a Q&A session with its covering analysts. Date: | Thursday, November 12, 2026 Time: | 4:30 p.m. Eastern time Dial-in: | 1-877-407-0792 International Dial-in: | 1-201-689-8263 Webcast: | TNON Conference Call Please dial in at least 10 minutes before the start of the call to ensure timely participation. An audio playback of the call will be available through November 26, 2026, on Tenon's Investor Relations website at http://ir.tenonmed.com/ or via telephone replay by dialing 1-844-512-2921 (USA) or 1-412-317-6671 (International). The access code will be 13763354. About Tenon Medical, Inc. Tenon Medical, Inc. is a medical device company dedicated to transforming care for patients with certain sacro-pelvic disorders. Tenon was incorporated in the State of Delaware in 2012 and currently offers two systems to treat a diseased sacroiliac joint (the "SI Joint"). The Company has developed The Catamaran™ SI Joint Fusion System that offers a novel, less invasive approach to the SI Joint using a single, robust titanium implant. In August 2025, the Company acquired substantially all of the assets of SiVantage, Inc. and SIMPL Medical, LLC, including the SImmetry+® SI Joint Fusion System, which treats disorders of the SI Joint through a minimally invasive lateral access solution that incorporates well-established orthopedic fusion principles. Since the national launch of The Catamaran System in October 2022, Tenon has been focused on three commercial opportunities: 1) primary SI Joint procedures, 2) revision procedures of failed SI Joint implants and 3) SI-Joint fusion adjunct to a spine fusion construct. For more information, please visit www.tenonmed.com. Information on the Company's website does not constitute a part of and is not incorporated by reference into this press release. The Tenon Medical logo shown above, and Catamaran®, PiSIF®, CAT PiSIF®, ETAD®, Posterior Inferior Sac…Read full document

LOS GATOS, CA / ACCESS Newswire / October 29, 2026 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company redefining care for patients with sacro-pelvic disorders, today announced plans to release financial results for the third quarter ended September 30, 2026 after market close on Thursday, November 12, 2026. The Company will also hold a conference call on the same day at 4:30 p.m. Eastern Time to discuss its financial results in further detail. The call will conclude with a Q&A session with its covering analysts. Date: | Thursday, November 12, 2026 Time: | 4:30 p.m. Eastern time Dial-in: | 1-877-407-0792 International Dial-in: | 1-201-689-8263 Webcast: | TNON Conference Call Please dial in at least 10 minutes before the start of the call to ensure timely participation. An audio playback of the call will be available through November 26, 2026, on Tenon's Investor Relations website at http://ir.tenonmed.com/ or via telephone replay by dialing 1-844-512-2921 (USA) or 1-412-317-6671 (International). The access code will be 13763354. About Tenon Medical, Inc. Tenon Medical, Inc. is a medical device company dedicated to transforming care for patients with certain sacro-pelvic disorders. Tenon was incorporated in the State of Delaware in 2012 and currently offers two systems to treat a diseased sacroiliac joint (the "SI Joint"). The Company has developed The Catamaran™ SI Joint Fusion System that offers a novel, less invasive approach to the SI Joint using a single, robust titanium implant. In August 2025, the Company acquired substantially all of the assets of SiVantage, Inc. and SIMPL Medical, LLC, including the SImmetry+® SI Joint Fusion System, which treats disorders of the SI Joint through a minimally invasive lateral access solution that incorporates well-established orthopedic fusion principles. Since the national launch of The Catamaran System in October 2022, Tenon has been focused on three commercial opportunities: 1) primary SI Joint procedures, 2) revision procedures of failed SI Joint implants and 3) SI-Joint fusion adjunct to a spine fusion construct. For more information, please visit www.tenonmed.com. Information on the Company's website does not constitute a part of and is not incorporated by reference into this press release. The Tenon Medical logo shown above, and Catamaran®, PiSIF®, CAT PiSIF®, ETAD®, Posterior Inferior Sacroiliac Fusion®, CAT SIJ Fusion System®, Catamaran SIJ Fusion System®, Catamaran Inferior Posterior Fusion System®, Catamaran Transfixation Fusion System®, Catamaran Transfixation Fusion Device®, SImmetry® are registered trademarks of Tenon Medical, Inc. MAINSAILTM is also a trademark of Tenon Medical, Inc. IR Contact: Shannon Devine 203-741-8811 MZ North America [email protected] SOURCE: Tenon Medical View the original press release on ACCESS Newswire

Related articleQuarter not tagged2026-08-20

Tenon Medical (TNON) Q2 2026 Earnings Call Transcript

Motley Fool
Image source: The Motley Fool. Thursday, Aug. 13, 2026 at 4:30 p.m. ET President and Chief Executive Officer - Steven Foster chief financial officer - Kevin Williamson Operator: Greetings, and welcome to the Tenon Medical Second Quarter 26 Financial Results and Corporate Update Conference Call. As a reminder, this call is being recorded. Your hosts today are Steven Foster, President and Chief Executive Officer and Kevin Williamson, chief financial officer. Mr. Foster and Mr. Williamson will present results of operations for the second quarter ended 06/30/2026 and provide a corporate update. A press release detailing these results was released today and is available on the Investor Relations section of our company's website www.tenonmed.com. Before we begin the formal presentation, I would like to remind everyone statements made on the call and webcast may include predictions estimates, and other information that might be considered forward looking. While these forward looking statements represent our current judgment on what the future holds, they are subject to risks and uncertainties that could cause actual results to differ materially. You are cautioned not to place undue reliance on these forward looking statements, which reflect our opinions only as of the date of this presentation. Please keep in mind that we are not obligating ourselves to revise or publicly release the results of any revision. To these forward looking statements in light of new information or future events. For a more complete discussion of these factors and other risks, you should review our quarterly and annual reports on file with the Securities and Exchange Commission at www.sec.gov. At this time, I would like to turn the call over to Tenon Medical's chief executive officer, Steven Foster. Please go ahead, sir. Steven Foster: Thank you, Joe, and good afternoon, everyone. I am pleased to welcome you to today's Second Quarter 26 financial results and corporate update conference call for Tenon Medical. Second quarter revenue was $1.3 million an increase of 127% over the second quarter last year and gross profit was $800 thousand an increase of 232%. Over the prior year period. Each was the highest we have reported in the second quarter. Gross margin was 64%, compared to 43% a year ago. Case volume grew across both the Catamaran and SImmetry+ platforms, and each incremental procedure…Read full document

Image source: The Motley Fool. Thursday, Aug. 13, 2026 at 4:30 p.m. ET President and Chief Executive Officer - Steven Foster chief financial officer - Kevin Williamson Operator: Greetings, and welcome to the Tenon Medical Second Quarter 26 Financial Results and Corporate Update Conference Call. As a reminder, this call is being recorded. Your hosts today are Steven Foster, President and Chief Executive Officer and Kevin Williamson, chief financial officer. Mr. Foster and Mr. Williamson will present results of operations for the second quarter ended 06/30/2026 and provide a corporate update. A press release detailing these results was released today and is available on the Investor Relations section of our company's website www.tenonmed.com. Before we begin the formal presentation, I would like to remind everyone statements made on the call and webcast may include predictions estimates, and other information that might be considered forward looking. While these forward looking statements represent our current judgment on what the future holds, they are subject to risks and uncertainties that could cause actual results to differ materially. You are cautioned not to place undue reliance on these forward looking statements, which reflect our opinions only as of the date of this presentation. Please keep in mind that we are not obligating ourselves to revise or publicly release the results of any revision. To these forward looking statements in light of new information or future events. For a more complete discussion of these factors and other risks, you should review our quarterly and annual reports on file with the Securities and Exchange Commission at www.sec.gov. At this time, I would like to turn the call over to Tenon Medical's chief executive officer, Steven Foster. Please go ahead, sir. Steven Foster: Thank you, Joe, and good afternoon, everyone. I am pleased to welcome you to today's Second Quarter 26 financial results and corporate update conference call for Tenon Medical. Second quarter revenue was $1.3 million an increase of 127% over the second quarter last year and gross profit was $800 thousand an increase of 232%. Over the prior year period. Each was the highest we have reported in the second quarter. Gross margin was 64%, compared to 43% a year ago. Case volume grew across both the Catamaran and SImmetry+ platforms, and each incremental procedure is now carrying meaningfully more profit. Looking at the first half as a whole, revenue was $2.7 million, an increase of 106% from $1.3 million in the first 6 months of 2025. Gross profit was $1.8 million an increase of 210% from $600 thousand at a gross margin of 66% compared with 44%. Our loss from operations for the 6 months was $6.6 million compared with $6.5 million a year ago essentially unchanged. While revenue doubled and gross profit dollars roughly tripled. Growth on the top line came from a higher number of Catamaran cases and continued meaningful SImmetry+ contribution since we acquired the SiVantage assets in August of last year. Position and distributor training is the leading indicator for us. And on that front, our training events increased 98% in the first half of 26 compared with the second half of 25. Gross margin expanded substantially year over year. At 54%, we are approximately 21 percentage points higher than the second quarter of last year and at 66% for the first half we are roughly 22 points higher than the same period in 2025. Increased revenue has contributed through improved absorption of fixed production overhead, and we are also benefiting from more streamlined commercial footprint and stronger field productivity. Beyond the financials, a few items from the quarter are worth noting. First, on the commercial side, our platform offering continues to progress the way we had planned. With physicians evaluating Catamaran and SImmetry+ as complementary tools. Inferior, posterior, and lateral approaches, to the same anatomy. As part of our continued investment in commercial activity, we have hired a seasoned professional sales lead to our East Coast sales team. And expect to add further sales heads and distributor partners in the back half of the year. Additionally, we saw a meaningful uptick in our physician and distributor training activity in Q2, driven by our newly opened Tampa sales and training office which has contributed to a record case value month in July and a strong start to Q3. Second, as it relates to regulatory matters, subsequent to the quarter end, on July 2, we announced that we received FDA 510(k) clearance for the catamaran SI joint fusion system. The updated clearance incorporates various instrument upgrades, as well as the reclassification of certain instruments from disposable to reusable status. Which is expected to improve system performance, while reducing ongoing per procedure costs previously associated with disposable instrumentation, improving margins which we expect to play out meaningfully beginning in Q3. Third, we have had a busy quarter with our R&D initiatives and are nearing multiple launches that we believe will be meaningful in this space. First, we have an enhanced SImmetry+ system that includes streamlined decortication, which will become clinically active in Q3 and is a significant improvement to this system. Second, we are nearing the final stages of development and approaching filing for 510(k) approval. Of an enhanced feature to the SImmetry+ implant which will make the implant even further differentiated. And third, we are excited about the progress we have made on a third approach to the space, an additional product offering to Catamaran and SImmetry+ that we believe meets a large unmet need in a very novel way. Fourth, as it relates to capital, on July 1, we closed a public offering of common stock or prefunded warrants. And common stock purchase warrants, for aggregate gross proceeds of $4.2 million Net proceeds are expected to be used for partial repayment of our outstanding convertible notes. Commercial expansion, clinical research, and general corporate purposes. Looking out over the rest of the year, our focus is narrow. Keep growing procedure volumes on both platforms continue aggressive physician training and education, accelerate key R&D projects, and protect the gross margin gains we have built over the past year as we scale. We have multiple ways to win in this market, and we intend to use them. With that, I will turn the call over to Kevin to discuss our financials. Kevin Williamson: Thank you, Steven. I will now provide a summarized review of our financial results. A full breakdown is available in our press release, crossed the wire this afternoon. Starting with the top line, second quarter revenue was 1.3 million a record for any second quarter in the company's history. And up 127% from $600 thousand a year ago. Revenue for the 6 months ended 06/30/2026 was 2.7 million. An increase of 106% compared to 1.3 million in the 6 months ended 06/30/2025. The increase in the quarter was driven by a large increase in the number of surgical procedures performed. As well as the addition of revenue related to the SImmetry+ system. Over the past 12 months, we have meaningfully increased our physician user base, and surgical case volume and we expect to continue to build on that momentum through Salesforce expansion increased physician and distributor engagement, and future product launches. Gross profit was $800 thousand or 64% of revenue in the second quarter, compared to $200 thousand or 43% of revenue a year ago. that is a 232% increase in dollar terms. And the highest for any second quarter in the company's history. On a margin basis, we picked up about 21 percentage points year over year. For the 6 months, gross profit was 1,$800 thousand or 66.2% of revenue, compared to 600 thousand or 44.0% of revenue. A 210% increase in dollars and roughly 22 percentage points. The improvement was primarily driven by higher revenue and lower costs in the period, driving further absorption of production overhead costs within cost of goods sold. We continue to expect to see our gross margin expand as revenue increases, and we further absorb fixed costs within our cost of sales. Operating expenses totaled $4.2 million in the second quarter, compared to $3.1 million in the second quarter of 25. For the 6 months, operating expenses totaled $8.4 million compared to $7.1 million in the prior year period. The increase in the quarter was primarily due to higher sales and marketing expenses, associated with higher revenue. In addition to higher research and development expenses, as we continue to work towards future product additions. Net loss was $4.1 million, or $12.35 per share in the second quarter, compared to a net loss of $2.8 million or $12.76 per share second quarter of 25. For the 6 months, net loss was $7.5 million or $23.23 per share compared to a net loss of $6.4 million or $39.91 per share the same period a year ago. The increase in net loss was primarily driven below the operating line. $900 thousand of non-cash interest expense related to the amortization of the original issue discount related to our convertible notes which was not present in the prior year period. We ended the quarter with $1.7 million in cash and cash equivalents, compared to $3.8 million as of 12/31/2025. Subsequent to quarter end on July 1, we closed the public offering with gross proceeds of $4.2 million which provides additional runway to fund our commercial, clinical, and development priorities. Overall, we believe the financial and strategic actions taken through the first half of 26 have positioned Tenon to drive continued growth in the second half and into 2027. While sustaining a streamlined and disciplined cost base and executing on our commercial and upcoming product launch initiatives. I will now hand the call back to Steven for closing comments. Steven Foster: Thank you, Kevin. In conclusion, we believe Tenon is delivering top line growth margin growth a cost structure that is expected to provide efficiencies as we expand our offerings. Significant progress has been made on vital R&D projects, promising a diversified and innovative portfolio of sacropelvic technologies over the next 6 to 9 months. Focus on commercial expansion, and execution positions Tenon to build on this momentum and deliver increasing value to patients providers, and our shareholders. I thank you all for attending, and I would like to hand the call over to our operator to begin our Q&A session with covering analysts. Joe? Operator: Thank you, sir. Ladies and gentlemen, if you would like to ask a question, please press 1 on your telephone keypad. And a confirmation tone will indicate your line is in the question queue. You may press 2 if you would like to remove your question from the queue. May be necessary to pick up your handset. Before pressing the star keys. And our first question comes from the line of Nicholas Sherwood with Maxim. Please proceed. Nicholas Sherwood: Hi, good evening. Thank you for taking my questions. Can you kind of just talk about any sort of advancements that have come in the SiVantage product pipeline? How you are feeling about the regulatory or the research and development on those? Steven Foster: Yes. Thanks, Nicholas. I appreciate the So when we did the SiVantage, transaction, they already had commercial activity in the SImmetry+ component of their of their offering. There are 3 major components to that technology. 1 was already released when we did the transaction. The second is an enhanced accreditation tool, which we mentioned will be out here in October for clinical use. And the second is in addition to the implant construct that we really think is going to be very novel and unique and answer some of the needs that have been communicated to us by our physician customers. So you are going to see a greatly enhanced SImmetry+ platform over the coming 2 to 6 months as we roll all of this stuff out. And we really believe that platform is going to become very attractive to physicians that do lateral oblique procedures. Secondarily, SiVantage had a novel posterior technology, posterior approach technology, that we are now just finishing testing on and preparing for an FDA submission in that arena. Very excited where that is going. Anxious to share more, probably in the next quarterly review. We will get into some details about what that technology looks like, how it is positioned, how it is targeted, and things of that nature. So the SiVantage portfolio is delivering as expected. Some really nice pipeline enhancements and what have you, and we are really excited about what is to come. Nicholas Sherwood: Yeah. that is that is an exciting thing. And my next question is, this summer, it might be more a slower period when it comes to training new physicians. Can you kind of talk about are there any special events or pushes that you are going to have through the end of this year, kind of that, you know, sort of back to school season so to speak, when it comes to bringing in new physicians and training them on your technology? Steven Foster: Yeah. Sure. Appreciate that. Look, I suppose with all of our activities, there is a little bit of seasonality. And certainly, it is true with physician training activities. We mentioned the opening of a training center in Tampa, and we are finding the demand to visit the facility to see the array of technologies that are there both in imaging as well as our own implant technology navigation technologies, things of that nature. Is really attractive. And, frankly, it is exceeded all of our expectations, the demand, the visits and what have you. So, you know, we mentioned some pretty significant growth in our training activity in the first half of 26 compared to 25. We attribute most of that to the new facility that we have invested in. In the in, frankly, the really cool environment and experience that is being delivered when physicians visit that site. So we are we are actually seeing an uptick, and I anticipate continued uptick, not only because the facility there but as we start rolling out the enhancements to SImmetry+ the new technologies we talked about, etcetera, there will be even more compelling reasons for physicians to visit and take a look at what is happened. Nicholas Sherwood: Awesome. Yeah. That sounds like there is some good progress there. Thank you for answering questions, and I will return to the queue. Steven Foster: Thanks, Nicholas. Operator: Thank you. This will conclude the question and answer session. And I would now like to turn the call back to Mr. Foster for his closing remarks. Steven Foster: Thank you, Joe. I would like to thank each of you for joining our earnings conference call today and look forward to continuing to update you on our ongoing progress and growth. If we were unable to answer any of your questions, please reach out to our IR firm, MZ Group, We will be more than happy to assist. With that, I wish everybody a good evening. Operator: This concludes today's conference. You may disconnect your lines at this time. And enjoy the rest of your day. Before you buy stock in Tenon Medical, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Tenon Medical wasn’t one of them. The 10 stocks that made the cut are built for long-term growth and could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $432,621!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,335,314!* That performance is why people listen. With a track record of beating the S&P 500 by nearly 5x, Stock Advisor offers a distinct advantage. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built for the long haul. See the 10 stocks » *Stock Advisor returns as of August 20, 2026. This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Tenon Medical (TNON) Q2 2026 Earnings Call Transcript was originally published by The Motley Fool

Related articleQuarter not tagged2026-08-14

Tenon Medical, Inc. Q2 2026 Earnings Call Summary

Moby
Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. Revenue growth of 127% was primarily driven by a significant increase in surgical procedure volumes and the integration of the SImmetry+ system acquired last year. Gross margin expanded by approximately 21 percentage points to 64%, attributed to improved absorption of fixed production overhead and a more streamlined commercial footprint. Management identifies physician and distributor training as a leading indicator for growth, noting a 98% increase in training events during the first half of 2026. The commercial strategy focuses on positioning Catamaran and SImmetry+ as complementary tools for inferior, posterior, and lateral approaches to the same anatomy. Operational efficiency improved through the reclassification of certain Catamaran instruments from disposable to reusable status following a recent FDA 510(k) clearance. The new Tampa sales and training office has exceeded expectations, contributing to a record case value month in July and a strong start to the third quarter. Management expects gross margin expansion to continue as revenue increases and fixed costs are further absorbed within the cost of sales. The company plans to add further sales heads and distributor partners in the second half of the year to support commercial expansion. An enhanced SImmetry+ system featuring streamlined decortication is scheduled to become clinically active in the third quarter of 2026. Tenon is nearing an FDA 510(k) filing for a novel posterior approach technology, which is currently finishing testing phases. A diversified portfolio of sacropelvic technologies is expected to be delivered over the next 6 to 9 months through multiple R&D launches. A public offering closed on July 1, 2026, generating $4.2 million in gross proceeds to fund commercial expansion, clinical research, and debt repayment. Net loss for the first six months of the year included $900 thousand of non-cash interest expense. related to the amortization of original issue discounts on convertible notes. FDA 510(k) clearance received on July 2 for the Catamaran system includes instrument upgrades expected to reduce per-procedure costs starting in Q3. Operating expenses increased to $4.2 million, primarily due to higher sales and marketing costs asso…Read full document

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. Revenue growth of 127% was primarily driven by a significant increase in surgical procedure volumes and the integration of the SImmetry+ system acquired last year. Gross margin expanded by approximately 21 percentage points to 64%, attributed to improved absorption of fixed production overhead and a more streamlined commercial footprint. Management identifies physician and distributor training as a leading indicator for growth, noting a 98% increase in training events during the first half of 2026. The commercial strategy focuses on positioning Catamaran and SImmetry+ as complementary tools for inferior, posterior, and lateral approaches to the same anatomy. Operational efficiency improved through the reclassification of certain Catamaran instruments from disposable to reusable status following a recent FDA 510(k) clearance. The new Tampa sales and training office has exceeded expectations, contributing to a record case value month in July and a strong start to the third quarter. Management expects gross margin expansion to continue as revenue increases and fixed costs are further absorbed within the cost of sales. The company plans to add further sales heads and distributor partners in the second half of the year to support commercial expansion. An enhanced SImmetry+ system featuring streamlined decortication is scheduled to become clinically active in the third quarter of 2026. Tenon is nearing an FDA 510(k) filing for a novel posterior approach technology, which is currently finishing testing phases. A diversified portfolio of sacropelvic technologies is expected to be delivered over the next 6 to 9 months through multiple R&D launches. A public offering closed on July 1, 2026, generating $4.2 million in gross proceeds to fund commercial expansion, clinical research, and debt repayment. Net loss for the first six months of the year included $900 thousand of non-cash interest expense. related to the amortization of original issue discounts on convertible notes. FDA 510(k) clearance received on July 2 for the Catamaran system includes instrument upgrades expected to reduce per-procedure costs starting in Q3. Operating expenses increased to $4.2 million, primarily due to higher sales and marketing costs associated with revenue growth and increased R&D investment. One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here. Management confirmed the SImmetry+ platform will see significant enhancements over the next 2 to 6 months, including a new decortication tool in October. Testing is being finalized for a novel posterior approach technology, with an FDA submission expected in the near future. The SiVantage portfolio is performing as expected, providing a foundation for lateral oblique procedure growth. Despite typical summer seasonality, the company is seeing an uptick in training demand due to the immersive environment of the new Tampa facility. The facility allows physicians to evaluate the full array of technologies, including imaging and navigation, which has driven record training activity. Management anticipates continued momentum as new product enhancements provide additional reasons for physicians to visit the site.

Related articleQuarter not tagged2026-08-14

Tenon Medical Inc (TNON) (Q2 2026) Earnings Call Highlights: Record Revenue Growth and FDA ...

GuruFocus.com
This article first appeared on GuruFocus. Release Date: August 13, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Second quarter revenue increased 127% year-over-year to $1.3 million, a record for the period. Gross margin expanded significantly to 64% in Q2 2026, up from 43% in Q2 2025. Received FDA 510(k) clearance for the Catamaran SI joint fusion system, with instrument upgrades expected to reduce per-procedure costs and improve margins. Training events increased 98% in the first half of 2026 compared to the second half of 2025, driving record case volume in July. Closed a $4.2 million public offering in July 2026, providing additional capital to fund commercial expansion and R&D initiatives. Net loss widened to $4.1 million in Q2 2026 from $2.8 million in Q2 2025, partly due to non-cash interest expense on convertible notes. Cash and cash equivalents declined to $1.7 million as of June 30, 2026, from $3.8 million at the end of 2025. Operating expenses increased to $4.2 million in Q2 2026 from $3.1 million in Q2 2025, driven by higher sales and marketing and R&D costs. The company continues to report significant operating losses, with a six-month loss from operations of $6.6 million, essentially unchanged year-over-year. Dependence on future product launches and regulatory approvals (e.g., enhanced Symmetry Plus features) to sustain growth, which carry execution and timing risks. Warning! GuruFocus has detected 7 Warning Signs with TNON. Is TNON fairly valued? Test your thesis with our free DCF calculator. Q: Can you talk about any advancements in the SI Bandage product pipeline and how you're feeling about the regulatory and R&D on those?A: Steve Foster, President and CEO, explained that the SciVantage transaction brought the Symmetry Plus platform, which has three major components. The first was already released, the second is an enhanced decortication tool expected for clinical use in October, and the third is a novel implant construct that addresses physician needs. He noted a greatly enhanced Symmetry Plus platform will roll out over the next two to six months, making it attractive for physicians preferring lateral and oblique procedures. Additionally, SciVantage's novel posterior approach technology is finishing testing and preparing for FDA submission, with more details expected in the next…Read full document

This article first appeared on GuruFocus. Release Date: August 13, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Second quarter revenue increased 127% year-over-year to $1.3 million, a record for the period. Gross margin expanded significantly to 64% in Q2 2026, up from 43% in Q2 2025. Received FDA 510(k) clearance for the Catamaran SI joint fusion system, with instrument upgrades expected to reduce per-procedure costs and improve margins. Training events increased 98% in the first half of 2026 compared to the second half of 2025, driving record case volume in July. Closed a $4.2 million public offering in July 2026, providing additional capital to fund commercial expansion and R&D initiatives. Net loss widened to $4.1 million in Q2 2026 from $2.8 million in Q2 2025, partly due to non-cash interest expense on convertible notes. Cash and cash equivalents declined to $1.7 million as of June 30, 2026, from $3.8 million at the end of 2025. Operating expenses increased to $4.2 million in Q2 2026 from $3.1 million in Q2 2025, driven by higher sales and marketing and R&D costs. The company continues to report significant operating losses, with a six-month loss from operations of $6.6 million, essentially unchanged year-over-year. Dependence on future product launches and regulatory approvals (e.g., enhanced Symmetry Plus features) to sustain growth, which carry execution and timing risks. Warning! GuruFocus has detected 7 Warning Signs with TNON. Is TNON fairly valued? Test your thesis with our free DCF calculator. Q: Can you talk about any advancements in the SI Bandage product pipeline and how you're feeling about the regulatory and R&D on those?A: Steve Foster, President and CEO, explained that the SciVantage transaction brought the Symmetry Plus platform, which has three major components. The first was already released, the second is an enhanced decortication tool expected for clinical use in October, and the third is a novel implant construct that addresses physician needs. He noted a greatly enhanced Symmetry Plus platform will roll out over the next two to six months, making it attractive for physicians preferring lateral and oblique procedures. Additionally, SciVantage's novel posterior approach technology is finishing testing and preparing for FDA submission, with more details expected in the next quarterly review. Q: Given that summer might be a slower period for training new physicians, are there any special events or pushes planned through the end of the year to bring in and train new physicians on your technology?A: Steve Foster, President and CEO, acknowledged some seasonality in physician training but highlighted the newly opened Tampa training center, which has exceeded expectations in demand and visits. The facility offers a compelling environment with imaging, implant technology, and navigation technologies. He anticipates continued uptick in training activity, not only due to the facility but also as new Symmetry Plus enhancements and technologies roll out, providing more reasons for physicians to visit. Q: What drove the significant revenue and gross margin growth in the second quarter of 2026?A: Kevin Williamson, CFO, reported second-quarter revenue of $1.3 million, up 127% year-over-year, driven by a large increase in surgical procedures and the addition of Symmetry Plus revenue. Gross profit rose 232% to $0.8 million, with gross margin expanding to 64% from 43%. The improvement was primarily due to higher revenue and lower fixed costs, driving better absorption of production overhead costs. He expects gross margin to continue expanding as revenue increases. Q: What are the key financial highlights for the first half of 2026?A: Kevin Williamson, CFO, noted first-half revenue was $2.7 million, up 106% from $1.3 million in 2025, with gross profit of $1.8 million, up 210%, and gross margin of 66.2% versus 44.0%. Operating expenses increased to $8.4 million from $7.1 million, driven by higher sales and marketing and R&D expenses. Net loss was $7.5 million, or $23.16 per share, compared to $6.4 million, or $39.91 per share, in the prior year, with the increase primarily due to non-cash interest expense from convertible notes. Q: How is the company positioned regarding capital and cash runway after the recent public offering?A: Kevin Williamson, CFO, stated the company ended the quarter with $1.7 million in cash, down from $3.8 million at the end of 2025. Subsequent to quarter end, on July 1, the company closed a public offering with gross proceeds of $4.2 million, providing additional runway to fund commercial, clinical, and development priorities. He believes the financial and strategic actions position Tenon to drive continued growth into 2027 while maintaining a disciplined cost base. Q: What is the significance of the FDA 510(k) clearance for the Catamaran SI joint fusion system?A: Steve Foster, President and CEO, announced that subsequent to the quarter end, on July 2, the company received FDA 510(k) clearance for the Catamaran system. The updated clearance incorporates instrument upgrades and reclassifies certain instruments from disposable to reusable status. This is expected to improve system performance while reducing ongoing per-procedure costs, meaningfully improving margins beginning in Q3. Q: What are the key R&D initiatives and upcoming product launches?A: Steve Foster, President and CEO, highlighted three R&D initiatives: an enhanced Symmetry Plus system with streamlined decortication becoming clinically active in Q3, an enhanced feature to the Symmetry Plus implant nearing final development and approaching FDA filing, and progress on a third approach to the space with a novel product offering that meets a large unmet need. He expects a diversified and innovative portfolio of sacral pelvic technologies over the next six to nine months. Q: How is the company's commercial strategy progressing, particularly with sales force expansion?A: Steve Foster, President and CEO, noted the platform offering is progressing as planned, with physicians evaluating Catamaran and Symmetry Plus as complementary tools for posterior and lateral approaches. The company hired a seasoned professional sales lead for the East Coast team and expects to add further sales heads and distributor partners in the back half of the year. Training events increased 98% in the first half of 2026 compared to the second half of 2025, contributing to a record case volume month in July. Q: What is the company's outlook for the rest of 2026?A: Steve Foster, President and CEO, stated the focus is narrow: keep growing procedure volumes on both platforms, continue aggressive physician training and education, accelerate key R&D projects, and protect gross margin gains as the company scales. He expressed confidence in multiple ways to win in the market and intends to use them. Q: What caused the increase in operating expenses in the second quarter?A: Kevin Williamson, CFO, explained that operating expenses totaled $4.2 million in Q2 2026, up from $3.1 million in Q2 2025. The increase was primarily due to higher sales and marketing expenses associated with higher revenue, as well as higher research and development expenses as the company continues to work toward future product additions. For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Related articleQuarter not tagged2026-08-13

Tenon Medical Reports Second Quarter 2026 Financial Results

ACCESS Newswire
~ Second Quarter 2026 Revenue of $1.3 Million, a 127% Increase Compared to Prior Year ~ ~ Second Quarter Gross Profit of $0.8 Million, a 232% Increase Compared to Prior Year; Gross Margin of 64% ~ ~ Received FDA 510(k) Clearance for Updated Catamaran® SI Joint Fusion System ~ ~ Physician and Distributor Training Events Increased 98% in 1H 2026 Compared to 2H 2025, Supporting Record Monthly Case Volume in July 2026 ~ ~ Closed $4.2 Million Public Offering Subsequent to Quarter End ~ LOS GATOS, CA / ACCESS Newswire / August 13, 2026 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon Medical" or the "Company"), a medical device company dedicated to transforming care for patients with certain sacro-pelvic disorders, today reported financial results for the second quarter ended June 30, 2026. Financial Results and Business Updates Second Quarter 2026 Results: Subsequent Updates On July 1, 2026, closed a best efforts public offering of common stock (or pre-funded warrants) and common stock purchase warrants for aggregate gross proceeds of $4.2 million, with net proceedsexpected to be used for partial repayment of convertible notes, commercial expansion, clinical research, and general corporate purposes. On July 2, 2026, the Company announced it received U.S. Food and Drug Administration 510(k) clearance for the Catamaran® SI Joint Fusion System. The updated clearance incorporates various instrument upgrades, as well as the reclassification of certain instruments from disposable to reusable status, which is expected to improve system performance while reducing ongoing per-procedure costs previously associated with disposable instrumentation. In July 2026, the Company recorded its highest monthly surgical case volume to date, following a 98% increase in physician and distributor training events in the first half of 2026 compared to the second half of 2025. On August 10, 2026, the Company effected a 1-for-35 reverse stock split of its common stock. The Company is currently working to regain compliance with Nasdaq listing requirements, including the minimum bid price rule. "Revenue of $1.3 million and gross profit of $0.8 million were each the highest we have reported in a second quarter, and the 64% gross margin demonstrates that the cost structure we've implemented is delivering as designed. Case volume grew across both the Catamaran® and SImmetry®+ platforms, and each…Read full document

~ Second Quarter 2026 Revenue of $1.3 Million, a 127% Increase Compared to Prior Year ~ ~ Second Quarter Gross Profit of $0.8 Million, a 232% Increase Compared to Prior Year; Gross Margin of 64% ~ ~ Received FDA 510(k) Clearance for Updated Catamaran® SI Joint Fusion System ~ ~ Physician and Distributor Training Events Increased 98% in 1H 2026 Compared to 2H 2025, Supporting Record Monthly Case Volume in July 2026 ~ ~ Closed $4.2 Million Public Offering Subsequent to Quarter End ~ LOS GATOS, CA / ACCESS Newswire / August 13, 2026 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon Medical" or the "Company"), a medical device company dedicated to transforming care for patients with certain sacro-pelvic disorders, today reported financial results for the second quarter ended June 30, 2026. Financial Results and Business Updates Second Quarter 2026 Results: Subsequent Updates On July 1, 2026, closed a best efforts public offering of common stock (or pre-funded warrants) and common stock purchase warrants for aggregate gross proceeds of $4.2 million, with net proceedsexpected to be used for partial repayment of convertible notes, commercial expansion, clinical research, and general corporate purposes. On July 2, 2026, the Company announced it received U.S. Food and Drug Administration 510(k) clearance for the Catamaran® SI Joint Fusion System. The updated clearance incorporates various instrument upgrades, as well as the reclassification of certain instruments from disposable to reusable status, which is expected to improve system performance while reducing ongoing per-procedure costs previously associated with disposable instrumentation. In July 2026, the Company recorded its highest monthly surgical case volume to date, following a 98% increase in physician and distributor training events in the first half of 2026 compared to the second half of 2025. On August 10, 2026, the Company effected a 1-for-35 reverse stock split of its common stock. The Company is currently working to regain compliance with Nasdaq listing requirements, including the minimum bid price rule. "Revenue of $1.3 million and gross profit of $0.8 million were each the highest we have reported in a second quarter, and the 64% gross margin demonstrates that the cost structure we've implemented is delivering as designed. Case volume grew across both the Catamaran® and SImmetry®+ platforms, and each incremental procedure is now carrying meaningfully more profit," said Steven M. Foster, President and CEO of Tenon Medical, Inc. "Along with record case volume, July added two more building blocks. The 510(k) clearance for our updated Catamaran® System moves several instruments from disposable to reusable, which we expect will take recurring cost out of cases we perform going forward, and the $4.2 million offering we closed on July 1 lets us reduce our convertible note balance while supporting our near-term commercial build-out and clinical program. Our focus through the balance of 2026 is straightforward: accelerating our development and product launch strategies, expanding training activities, and maintaining discipline on spend." Second Quarter 2026 Financial Results Revenue was $1.3 million in the second quarter of 2026, an increase of 127% compared to $0.6 million in the same period of 2025. Revenue for the six months ended June 30, 2026 was $2.7 million, an increase of 106% compared to $1.3 million in the six months ended June 30, 2025. The increase in revenue for the three months ended June 30, 2026 as compared to 2025 was primarily due to a significant increase in the number of surgical procedures, including the addition of revenue related to the SImmetry®+ System. Gross profit was $0.8 million, or 64% of revenue, in the second quarter of 2026, compared to $0.2 million, or 43% of revenue, in the second quarter of 2025. For the six months ended June 30, 2026, gross profit was $1.8 million, or 66% of revenue, compared to $0.6 million, or 44% of revenue, for the six months ended June 30, 2025. The twenty-one point gross margin improvement in the three months ended June 30, 2026 was primarily driven by higher revenue and lower fixed costs in the period, driving further absorption of production overhead costs within cost of goods sold. Operating expenses totaled $4.2 million in the second quarter of 2026, compared to $3.1 million in the second quarter of 2025. For the six months ended June 30, 2026, operating expenses totaled $8.4 million, compared to $7.1 million in the prior year period. The increase in the three months ended June 30, 2026 was primarily due to higher sales expenses associated with higher revenue, the expanded commercial team and ongoing rollout of the SImmetry®+ System, in addition to higher research and development expenses as we continue to work towards future product additions. Net loss was $4.1 million, or $12.35 per share, in the second quarter of 2026, compared to a net loss of $2.8 million, or $12.76 per share, in the second quarter of 2025. For the six months ended June 30, 2026, net loss was $7.5 million, or $23.16 per share, compared to a net loss of $6.4 million, or $39.91 per share, in the same year ago period. The year-over-year increase in the three months ended June 30, 2026 was largely driven below the line by non-cash interest expense of $0.9 million, which includes amortization of the original issue discount related to our convertible notes, partially offset by higher other income of $0.1 million, related to gains on the change in fair value of our derivative liability. As of June 30, 2026, cash and cash equivalents totaled $1.7 million, compared to $3.8 million at December 31, 2025. Subsequent to quarter end in July 2026, Tenon closed a public offering with gross proceeds of $4.2 million, with net proceeds of approximately $3.6 million. The Company intends to use the net proceeds for partial repayment of outstanding convertible notes, commercial expansion, clinical research, product development, and general corporate purposes. The Company's $5.2 million convertible notes mature on September 11, 2026 (extendable to December 11, 2026). A portion of the July 2026 offering proceeds will be used toward partial repayment; there can be no assurance the Company will repay or refinance these obligations in full. Second Quarter 2026 Earnings Conference Call Management will host a conference call at 4:30 p.m. ET (1:30 p.m. PT) today, August 13, 2026, to discuss Tenon's second quarter 2026 financial results, provide a corporate update, and conclude with Q&A with the Company's covering analyst. To participate, please use the following information: Please dial in at least 10 minutes before the start of the call to ensure timely participation. An audio playback of the call will be available through August 27, 2026, on Tenon's Investor Relations website at http://ir.tenonmed.com/ or via telephone replay by dialing 1-844-512-2921 (USA) or 1-412-317-6671 (International). The access code will be 13761819. About Tenon Medical, Inc. Tenon Medical, Inc. is a medical device company dedicated to transforming care for patients with certain sacro-pelvic disorders. Tenon was incorporated in the State of Delaware in 2012 and currently offers two systems to treat a diseased sacroiliac joint (the "SI Joint"). The Company has developed The Catamaran® SI Joint Fusion System that offers a novel, less invasive approach to the SI Joint using a single, robust titanium implant. In August 2025, the Company acquired substantially all the assets of SiVantage, Inc. and SIMPL Medical, LLC, including the SImmetry+® SI Joint Fusion System, which treats disorders of the SI Joint through a minimally invasive lateral access solution that incorporates well-established orthopedic fusion principles. Since the national launch of The Catamaran System in October 2022, Tenon is focused on three commercial opportunities: 1) primary SI Joint procedures, 2) revision procedures of failed SI Joint implants and 3) SI-Joint fusion adjunct to a spine fusion construct. For more information, please visit www.tenonmed.com. Information on the Company's website does not constitute a part of and is not incorporated by reference into this press release. The Tenon Medical logo shown above, and Catamaran®, PiSIF®, CAT PiSIF®, ETAD®, Posterior Inferior Sacroiliac Fusion®, CAT SIJ Fusion System®, Catamaran SIJ Fusion System®, Catamaran Inferior Posterior Fusion System®, Catamaran Transfixation Fusion System®, Catamaran Transfixation Fusion Device®, SImmetry® are registered trademarks of Tenon Medical, Inc. MAINSAIL™, and SImmetry+ are also trademarks of Tenon Medical, Inc. Safe Harbor This press release contains "forward-looking statements," which are statements related to events, results, activities or developments that Tenon expects, believes or anticipates will or may occur in the future. Forward-looking statements often contain words such as "intends," "estimates," "anticipates," "hopes," "projects," "plans," "expects," "seek," "believes," "see," "should," "will," "would," "target," and similar expressions and the negative versions thereof. These forward-looking statements include, but are not limited to, statements regarding the anticipated use of proceeds from the July 2026 offering, the Company's ability to continue as a going concern, the Company's ability to regain and maintain compliance with Nasdaq listing requirements; its plans to raise additional capital on acceptable terms or at all, the expected benefits of the updated Catamaran SI Joint Fusion System, future product development, commercial expansion plans, cost structure improvements, and anticipated case volume growth. Such statements are based on Tenon's experience and perception of current conditions, trends, expected future developments and other factors it believes are appropriate under the circumstances, and speak only as of the date made. Forward-looking statements are inherently uncertain and actual results may differ materially from assumptions, estimates or expectations reflected or contained in the forward-looking statements as a result of various factors. For details on the uncertainties that may cause Tenon's actual results to be materially different than those expressed in any forward-looking statements, please review Tenon's Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and updated from time to time in our Form 10-Q filings and in our other public filings on file with the SEC at www.sec.gov, particularly the information contained in the section entitled "Risk Factors." We undertake no obligation to publicly update or revise any forward-looking statements to reflect new information or future events or otherwise unless required by law. IR Contact: Shannon Devine203-741-8811MZ North [email protected] Tenon Medical, Inc.Condensed Balance Sheets (Unaudited)(In thousands, except share data) Tenon Medical, Inc.Condensed Statements of Operations and Comprehensive Loss (Unaudited)(In thousands, except per share data) SOURCE: Tenon Medical, Inc. View the original press release on ACCESS Newswire

TranscriptFY2026 Q22026-08-13

FY2026 Q2 earnings call transcript

Earnings source - 26 paragraphs
Operator

Welcome to the Tenon Medical second quarter 2026 financial results and corporate update conference call. As a reminder, this call is being recorded. Your hosts today are Steve Foster, President and Chief Executive Officer, and Kevin Williamson, Chief Financial Officer. Mr. Foster and Mr. Williamson will present results of operations for the second quarter ended June 30th, 2026 and provide a corporate update. A press release detailing these results was released today and is available on the Investor Relations section of our company's website, www.tenonmed.com. Before we begin the formal presentation, I would like to remind everyone that statements made on the call and webcast may include predictions, estimates, and other information that might be considered forward-looking. While these forward-looking statements represent our current judgment on what the future holds, they are subject to risks and uncertainties that could cause actual results to differ materially.

Operator

You are cautioned not to place undue reliance on these forward-looking statements, which reflect our opinions only as of the date of this presentation. Please keep in mind that we are not obligating ourselves to revise or publicly release the results of any revision to these forward-looking statements in light of new information or future events. For a more complete discussion of these factors and other risks, you should review our quarterly and annual reports on file with the Securities and Exchange Commission at www.sec.gov. At this time, I would like to turn the call over to Tenon Medical's Chief Executive Officer, Steve Foster. Please go ahead, sir.

Steve Foster

Thank you, Joe, and good afternoon, everyone. I am pleased to welcome you to today's second quarter 2026 financial results and corporate update conference call for Tenon Medical. Second quarter revenue was $1.3 million, an increase of 127% over the second quarter last year, and gross profit was $0.8 million, an increase of 232% over the prior year period. Each was the highest we have reported in a second quarter. Gross margin was 64% compared to 43% a year ago. Case volume grew across both the Catamaran and SImmetry+ platforms, and each incremental procedure is now carrying meaningful more profit. Looking at the first half as a whole, revenue was $2.7 million, an increase of 106% from $1.3 million in the first six months of 2025. Gross profit was $1.8 million, an increase of 210% from $0.6 million at a gross margin of 66% compared with 44%.

Steve Foster

Our loss from operations for the six months was $6.6 million, compared with $6.5 million a year ago, essentially unchanged, while revenue doubled and gross profit dollars roughly tripled. Growth on the top line came from a higher number of Catamaran cases and continued meaningful SImmetry+ contribution since we acquired the SiVantage assets in August of last year. Physician and distributor training is a leading indicator for us, and on that front, our training events increased 98% in the first half of 2026 compared with the second half of 2025. Gross margin expanded substantially year-over-year. At 64%, we are approximately 21 percentage points higher than the second quarter of last year. At 66% for the first half, we are roughly 22 points higher than the same period in 2025.

Steve Foster

Increased revenue has contributed through improved absorption of fixed production overhead, and we are also benefiting from more streamlined commercial footprint and stronger field productivity. Beyond the financials, a few items from the quarter are worth noting. First, on the commercial side, our platform offering continues to progress the way we had planned, with physicians evaluating Catamaran and SImmetry+ as complementary tools, inferior posterior lateral approaches to the same anatomy. As part of our continued investment in commercial activity, we've hired a seasoned professional sales lead to our East Coast sales team and expect to add further sales heads and distributor partners in the back half of the year.

Steve Foster

Additionally, we saw a meaningful uptick in our physician and distributor training activity in Q2, driven by our newly opened Tampa sales and training office, which has contributed to a record case volume month in July and a strong start to Q3. Second, as it relates to regulatory matters, subsequent to the quarter end, on July 2nd, we announced that we received FDA 510(k) clearance for the Catamaran SI Joint Fusion System. The updated clearance incorporates various instrument upgrades, as well as the reclassification of certain instruments from disposable to reusable status, which is expected to improve system performance while reducing ongoing per-procedure costs previously associated with disposable instrumentation and improving margin, which we expect to play out meaningfully beginning in Q3. Third, we have had a busy quarter with our R&D initiatives and are nearing multiple launches that we believe will be meaningful in this space.

Steve Foster

First, we have an enhanced SImmetry+ system that includes streamlined decortication, which will become clinically active in Q3 and is a significant improvement to this system. Second, we are nearing the final stages of development and approaching filing for 510(k) approval of an enhanced feature to the SImmetry+ implant, which will make the implant even further differentiated. Third, we are excited about the progress we have made on a third approach to the space in an additional product offering to Catamaran and SImmetry+ that we believe meets a large unmet need in a very novel way. Fourth, as it relates to capital, on July 1, we closed a public offering of common stock or pre-funded warrants and common stock purchase warrants for aggregate gross proceeds of $4.2 million.

Steve Foster

Net proceeds are expected to be used for partial repayment of our outstanding convertible notes, commercial expansion, clinical research, and general corporate purposes. Looking out over the rest of the year, our focus is narrow: keep growing procedure volumes on both platforms, continue aggressive physician training and education, accelerate key R&D projects, and protect the gross margin gains we have built over the past year as we scale. We have multiple ways to win in this market, and we intend to use them. With that, I'll turn the call over to Kevin to discuss our financials.

Kevin Williamson

Thank you, Steve. I will now provide a summarized review of our financial results. A full breakdown is available in our press release that crossed the wire this afternoon. Starting with the top line, second quarter revenue was $1.3 million, a record for any second quarter in the company's history, and up 127% from $0.6 million a year ago. Revenue for the six months ended June 30th, 2026 was $2.7 million, an increase of 106% compared to $1.3 million in the six months ended June 30th, 2025. The increase in the quarter was driven by a large increase in the number of surgical procedures performed, as well as the addition of revenue related to the SImmetry+ system.

Kevin Williamson

Over the past 12 months, we have meaningfully increased our physician user base and surgical case volume, and we expect to continue to build on that momentum through sales force expansion, increased physician and distributor engagement, and future product launches. Gross profit was $0.8 million, or 64% of revenue in the second quarter, compared to $0.2 million or 43% of revenue a year ago. That's a 232% increase in dollar terms and the highest for any second quarter in the company's history. On a margin basis, we picked up about 21 percentage points year-over-year. For the six months, gross profit was $1.8 million or 66.2% of revenue, compared to $0.6 million or 44.0% of revenue, a 210% increase in dollars and roughly 22 percentage points.

Kevin Williamson

The improvement was primarily driven by higher revenue and lower fixed costs in the period, driving further absorption of production overhead costs within cost of goods sold. We continue to expect to see our gross margin expand as revenue increases and we further absorb fixed costs within our cost of sales. Operating expenses totaled $4.2 million in the second quarter, compared to $3.1 million in the second quarter of 2025. For the six months, operating expenses totaled $8.4 million compared to $7.1 million in the prior year period. The increase in the quarter was primarily due to higher sales and marketing expenses associated with higher revenue, in addition to higher research and development expenses as we continue to work towards future product additions.

Kevin Williamson

Net loss was $4.1 million or $12.35 per share in the second quarter, compared to a net loss of $2.8 million or $12.76 per share in the second quarter of 2025. For the six months, net loss was $7.5 million or $23.16 per share, compared to a net loss of $6.4 million or $39.91 per share in the same period a year ago. The increase in net loss was primarily driven below the operating line by $0.9 million of non-cash interest expense related to the amortization of the original issue discount related to our convertible notes, which was not present in the prior year period. We ended the quarter with $1.7 million in cash and cash equivalents, compared to $3.8 million as of December 31, 2025.

Kevin Williamson

Subsequent to quarter end, on July 1st, we closed the public offering with gross proceeds of $4.2 million, which provides additional runway to fund our commercial, clinical, and development priorities. Overall, we believe the financial and strategic actions taken through the first half of 2026 have positioned Tenon to drive continued growth in the second half and into 2027 while sustaining a streamlined and disciplined cost base and executing on our commercial and upcoming product launch initiatives. I'll now hand the call back to Steve for closing comments.

Steve Foster

Thank you, Kevin. In conclusion, we believe Tenon is delivering top-line growth, margin growth, and a cost structure that is expected to provide efficiencies as we expand our offerings. Significant progress has been made on vital R&D projects, promising a diversified and innovative portfolio of sacropelvic technologies over the next six to nine months. Our focus on commercial expansion and execution positions Tenon to build on this momentum and deliver increasing value to patients, providers, and our shareholders. I thank you all for attending, and now I'd like to hand the call over to our operator to begin our Q&A session with covering analysts. Joe?

Operator

Thank you, sir. Ladies and gentlemen, if you would like to ask a question, please press star one on your telephone keypad, and a confirmation tone will indicate your line is in the question queue. You may press star two if you would like to remove your question from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star keys. Our first question comes from the line of Nicholas Sherwood with Maxim. Please proceed.

Nicholas Sherwood

Hi, good evening. Thank you for taking my questions. Can you just talk about any sort of advancements that have come in the SiVantage product pipeline? How you're feeling about the regulatory or the research and development on those?

Steve Foster

Yeah. Thanks, Nicholas. I appreciate the question. When we did the SiVantage transaction, they already had commercial activity in the SImmetry+ component of their offering. There are three major components to that technology. One was already released when we did the transaction. The second is an enhanced decortication tool, which we mentioned will be out here in October, for clinical use. The second is an addition to the implant construct that we really think is going to be very novel and unique and answer some of the needs that have been communicated to by our physician customers. You're going to see a greatly enhanced SImmetry+ platform over the coming two to six months, as we roll all of this stuff out. We really believe that that platform's going to become very attractive to physicians that prefer lateral and oblique procedures.

Steve Foster

Secondarily, SiVantage had a novel posterior approach technology that we are now just finishing testing on and preparing for an FDA submission in that arena. Very excited where that's going. Anxious to share more, probably in the next quarterly review. We'll get into some details about what that technology looks like, how it's positioned, how it's targeted, and things of that nature. The SiVantage portfolio is delivering as expected, some really nice pipeline enhancements and what have you, and we're really excited about what's to come.

Nicholas Sherwood

Yeah, that's an exciting thing. My next question is, the summer might be a slower period when it comes to training new physicians. Can you talk about, are there any special events or pushes that you're going to have through the end of this year? Kind of that back to school season, so to speak, when it comes to bringing in new physicians and training them on your technology?

Steve Foster

Yeah, sure. Appreciate that. Look, I suppose with all of our activities, there's a little bit of seasonality. Certainly it's true with physician training activities. We mentioned the opening of a training center in Tampa, and we're finding the demand to visit the facility to see the array of technologies that are there, both in imaging as well as our own implant technology, navigation technologies, things of that nature, is really attractive. Frankly, it's exceeded all of our expectations, the demand, the visits, and what have you. We mentioned some pretty significant growth in our training activity in the first half of 2026 compared to 2025, and we attribute most of that to the new facility that we've invested in, and frankly, the really cool environment, and experience that's being delivered when physicians visit that site.

Steve Foster

We are actually seeing an uptick, and I anticipate continued uptick, not only because of the facility there, but as we start rolling out the enhancements to SImmetry+, the new technologies we talked about, et cetera, there will be even more compelling reasons for physicians to visit and take a look at what is happening.

Nicholas Sherwood

Awesome. Yeah. That sounds like there is some good progress there. Thank you for answering my questions, and I will return to the queue.

Steve Foster

Thanks, Nicholas.

Operator

Thank you. This will conclude the question and answer session, and I would now like to turn the call back to Mr. Foster for his closing remarks.

Steve Foster

Great. Thank you, Joe. I would like to thank each of you for joining our earnings conference call today and look forward to continuing to update you on our ongoing progress and growth. If we were unable to answer any of your questions, please reach out to our IR firm, MZ Group. We will be more than happy to assist. With that, I wish everybody a good evening.

Operator

This concludes today's conference. You may disconnect your lines at this time and enjoy the rest of your day.

Related articleQuarter not tagged2026-08-12

Earnings To Watch: Tenon Medical Inc (TNON) Q2 2026 -- GF Value Sees 89% Downside

GuruFocus.com

This article first appeared on GuruFocus. Tenon Medical Inc (NASDAQ:TNON) is set to release its Q2 2026 earnings on Aug 13, 2026. The consensus estimate for Q2 2026 revenue is 1.54 million, and the earnings are expected to come in at -0.24 per share. The full year 2026's revenue is expected to be $6.59 million and the earnings are expected to be $-0.85 per share. More detailed estimate data can be found on the Forecast page Warning! GuruFocus has detected 7 Warning Signs with TNON. Is TNON fairly valued? Test your thesis with our free DCF calculator. Revenue estimates for Tenon Medical Inc (NASDAQ:TNON) have increased from $6.42 million to $6.59 million for the full year 2026 and increased from $9.66 million to $9.71 million for 2027 over the past 90 days. Earnings estimates for Tenon Medical Inc (NASDAQ:TNON) have increased from $-0.88 per share to $-0.85 per share for the full year 2026 and increased from $-0.63 per share to $-0.61 per share for 2027 over the past 90 days. In the previous quarter of 2026-03-31, Tenon Medical Inc's (NASDAQ:TNON) actual revenue was $1.38 million, which beat analysts' revenue expectations of $1.23 million by 11.75%. Tenon Medical Inc's (NASDAQ:TNON) actual earnings were $-0.31 per share, which met analysts' earnings expectations. After releasing the results, Tenon Medical Inc (NASDAQ:TNON) was down by -11.55% in one day. Based on the one-year price targets offered by 2 analysts, the average target price for Tenon Medical Inc (NASDAQ:TNON) is $2.63 with a high estimate of $3.00 and a low estimate of $2.25. The average target implies an downside of -57.25% from the current price of $6.14. Based on GuruFocus estimates, the estimated GF Value for Tenon Medical Inc (NASDAQ:TNON) in one year is $0.67, suggesting an downside of -89.09% from the current price of $6.14. Based on the consensus recommendation from 2 brokerage firms, Tenon Medical Inc's (NASDAQ:TNON) average brokerage recommendation is currently 2.00, indicating a "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.

As of 2026-11-14 • Updated weeklySource: Earnings sourceIngestion runbook